

# Wiesje M Van Der Flier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1804743/publications.pdf>

Version: 2024-02-01

846  
papers

46,559  
citations

1981

104  
h-index

4305

179  
g-index

970  
all docs

970  
docs citations

970  
times ranked

35935  
citing authors

#	ARTICLE	IF	CITATIONS
1	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 844-852.	0.4	1,863
2	Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. <i>Nature Genetics</i> , 2019, 51, 404-413.	9.4	1,625
3	Alzheimer's disease. <i>Lancet, The</i> , 2021, 397, 1577-1590.	6.3	1,530
4	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	3.8	1,166
5	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 385.	3.8	1,009
6	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	9.4	700
7	The characterisation of subjective cognitive decline. <i>Lancet Neurology, The</i> , 2020, 19, 271-278.	4.9	627
8	Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 126-135.	0.9	588
9	Prevalence of Amyloid PET Positivity in Dementia Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1939.	3.8	501
10	The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. <i>Ageing Research Reviews</i> , 2016, 25, 13-23.	5.0	455
11	Consensus classification of posterior cortical atrophy. <i>Alzheimer's and Dementia</i> , 2017, 13, 870-884.	0.4	423
12	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. <i>Brain</i> , 2015, 138, 2732-2749.	3.7	397
13	Implementation of subjective cognitive decline criteria in research studies. <i>Alzheimer's and Dementia</i> , 2017, 13, 296-311.	0.4	375
14	Epidemiology and risk factors of dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, v2-v7.	0.9	374
15	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. <i>Lancet Neurology, The</i> , 2022, 21, 66-77.	4.9	360
16	Early-Versus Late-Onset Alzheimer's Disease: More than Age Alone. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1401-1408.	1.2	359
17	Vascular cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18003.	18.1	358
18	Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. <i>Neurobiology of Aging</i> , 2013, 34, 2023-2036.	1.5	355

#	ARTICLE	IF	CITATIONS
19	Progression of White Matter Hyperintensities and Incidence of New Lacunes Over a 3-Year Period. <i>Stroke</i> , 2008, 39, 1414-1420.	1.0	348
20	Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2012, 33, 2018-2028.	1.5	337
21	Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. <i>BMC Neuroscience</i> , 2009, 10, 101.	0.8	317
22	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S63-S86.	1.2	317
23	Hippocampal atrophy rates in Alzheimer disease. <i>Neurology</i> , 2009, 72, 999-1007.	1.5	315
24	Small Vessel Disease and General Cognitive Function in Nondisabled Elderly. <i>Stroke</i> , 2005, 36, 2116-2120.	1.0	311
25	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 313-327.	1.2	307
26	Amyloid- $\beta$ (1-42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease. <i>Clinical Chemistry</i> , 2010, 56, 248-253.	1.5	301
27	Visual assessment of posterior atrophy development of a MRI rating scale. <i>European Radiology</i> , 2011, 21, 2618-2625.	2.3	299
28	Brain microbleeds and Alzheimer's disease: innocent observation or key player?. <i>Brain</i> , 2011, 134, 335-344.	3.7	291
29	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. <i>Alzheimer's and Dementia</i> , 2019, 15, 888-898.	0.4	290
30	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015, 138, 1327-1338.	3.7	284
31	Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE $\epsilon$ 4 allele. <i>Lancet Neurology</i> , The, 2011, 10, 280-288.	4.9	273
32	Prevalence and severity of microbleeds in a memory clinic setting. <i>Neurology</i> , 2006, 66, 1356-1360.	1.5	270
33	Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: The CADDementia challenge. <i>NeuroImage</i> , 2015, 111, 562-579.	2.1	266
34	Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. <i>Neurology</i> , 2012, 78, 47-54.	1.5	255
35	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1180-1190.	0.4	254
36	Blood-brain barrier P-glycoprotein function in Alzheimer's disease. <i>Brain</i> , 2012, 135, 181-189.	3.7	252

#	ARTICLE	IF	CITATIONS
37	Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. <i>Neuroradiology</i> , 2007, 49, 967-976.	1.1	251
38	The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014, 10, 713.	0.4	249
39	Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. <i>Brain</i> , 2008, 131, 3286-3298.	3.7	246
40	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019, 15, 465-476.	0.4	232
41	Suspected non-Alzheimer disease pathophysiology "concept and controversy. <i>Nature Reviews Neurology</i> , 2016, 12, 117-124.	4.9	230
42	Plasma Amyloid as Prescreeener for the Earliest Alzheimer Pathological Changes. <i>Annals of Neurology</i> , 2018, 84, 648-658.	2.8	230
43	Amsterdam Dementia Cohort: Performing Research to Optimize Care. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1091-1111.	1.2	228
44	A meta-analysis of genome-wide association studies identifies multiple longevity genes. <i>Nature Communications</i> , 2019, 10, 3669.	5.8	214
45	Cerebral Blood Flow Measured with 3D Pseudocontinuous Arterial Spin-labeling MR Imaging in Alzheimer Disease and Mild Cognitive Impairment: A Marker for Disease Severity. <i>Radiology</i> , 2013, 267, 221-230.	3.6	206
46	Patients With Alzheimer Disease With Multiple Microbleeds. <i>Stroke</i> , 2009, 40, 3455-3460.	1.0	202
47	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	1.2	197
48	Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. <i>Human Brain Mapping</i> , 2015, 36, 4421-4437.	1.9	196
49	Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer's disease. <i>NeuroImage</i> , 2012, 59, 3085-3093.	2.1	190
50	Incident lacunes influence cognitive decline. <i>Neurology</i> , 2011, 76, 1872-1878.	1.5	183
51	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 1275.	4.5	183
52	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.	0.4	179
53	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014, 23, 6139-6146.	1.4	178
54	Longitudinal Cognitive Decline in Subcortical Ischemic Vascular Disease "The LADIS Study. <i>Cerebrovascular Diseases</i> , 2009, 27, 384-391.	0.8	167

#	ARTICLE	IF	CITATIONS
55	Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 439-442.	0.9	165
56	Standardized Assessment of Automatic Segmentation of White Matter Hyperintensities and Results of the WMH Segmentation Challenge. <i>IEEE Transactions on Medical Imaging</i> , 2019, 38, 2556-2568.	5.4	165
57	Cerebrospinal fluid A $\beta$ 42 is the best predictor of clinical progression in patients with subjective complaints. <i>Alzheimer's and Dementia</i> , 2013, 9, 481-487.	0.4	164
58	Relationship of Cerebrospinal Fluid Markers to <sup>11</sup> C-PiB and <sup>18</sup> F-FDDNP Binding. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1464-1470.	2.8	162
59	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. <i>Neurology</i> , 2013, 80, 1048-1056.	1.5	161
60	CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2007, 28, 1070-1074.	1.5	160
61	Profile of Cognitive Impairment in Chronic Heart Failure. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 1764-1770.	1.3	160
62	Impact of molecular imaging on the diagnostic process in a memory clinic. <i>Alzheimer's and Dementia</i> , 2013, 9, 414-421.	0.4	159
63	A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Annals of Clinical Biochemistry</i> , 2009, 46, 235-240.	0.8	157
64	Memory complaints in patients with normal cognition are associated with smaller hippocampal volumes. <i>Journal of Neurology</i> , 2004, 251, 671-5.	1.8	156
65	Early Onset Alzheimer's Disease is Associated with a Distinct Neuropsychological Profile. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 101-108.	1.2	156
66	Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2014-2022.	1.5	156
67	Age and diagnostic performance of Alzheimer disease CSF biomarkers. <i>Neurology</i> , 2012, 78, 468-476.	1.5	154
68	Global estimates on the number of persons across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2023, 19, 658-670.	0.4	146
69	Longitudinal imaging of Alzheimer pathology using [11C]PiB, [18F]FDDNP and [18F]FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 990-1000.	3.3	145
70	Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study. <i>Neurobiology of Aging</i> , 2013, 34, 128-136.	1.5	145
71	Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage. <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 58.	1.7	143
72	Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. <i>Alzheimer's and Dementia</i> , 2018, 14, 707-722.	0.4	143

#	ARTICLE	IF	CITATIONS
73	White Matter Hyperintensities Rather Than Lacunar Infarcts Are Associated With Depressive Symptoms in Older People: The LADIS Study. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 834-841.	0.6	141
74	Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 353-366.	1.4	140
75	Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. <i>JAMA Neurology</i> , 2014, 71, 855.	4.5	140
76	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	5.8	140
77	Differential diagnosis of neurodegenerative diseases using structural MRI data. <i>NeuroImage: Clinical</i> , 2016, 11, 435-449.	1.4	137
78	Whole-Brain Atrophy Rate and Cognitive Decline: Longitudinal MR Study of Memory Clinic Patients. <i>Radiology</i> , 2008, 248, 590-598.	3.6	133
79	Declining functional connectivity and changing hub locations in Alzheimer's disease: an EEG study. <i>BMC Neurology</i> , 2015, 15, 145.	0.8	133
80	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133
81	Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study. <i>Brain</i> , 2017, 140, 1466-1485.	3.7	132
82	Prevalence of amyloid- $\beta$ pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.	2.8	132
83	Brain magnetic resonance imaging abnormalities in patients with heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 1003-1009.	2.9	130
84	CSF biomarkers predict rate of cognitive decline in Alzheimer disease. <i>Neurology</i> , 2009, 73, 1353-1358.	1.5	130
85	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. <i>Neurology</i> , 2012, 79, 1809-1816.	1.5	129
86	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 118.	3.0	129
87	Progression of Mild Cognitive Impairment to Dementia. <i>Stroke</i> , 2009, 40, 1269-1274.	1.0	128
88	Magnetization transfer imaging in normal aging, mild cognitive impairment, and Alzheimer's disease. <i>Annals of Neurology</i> , 2002, 52, 62-67.	2.8	127
89	Hippocampal atrophy in Alzheimer disease: Age matters. <i>Neurology</i> , 2006, 66, 236-238.	1.5	127
90	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid- $\beta$ 1-42 Analysis Results. <i>Clinical Chemistry</i> , 2018, 64, 576-585.	1.5	126

#	ARTICLE	IF	CITATIONS
91	Microglial activation in healthy aging. <i>Neurobiology of Aging</i> , 2012, 33, 1067-1072.	1.5	125
92	Brain atrophy accelerates cognitive decline in cerebral small vessel disease. <i>Neurology</i> , 2012, 78, 1785-1792.	1.5	125
93	Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. <i>Current Medical Research and Opinion</i> , 2008, 24, 2561-2574.	0.9	124
94	Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging. <i>Stroke</i> , 2011, 42, 1894-1900.	1.0	124
95	Global Prevalence of Young-Onset Dementia. <i>JAMA Neurology</i> , 2021, 78, 1080.	4.5	124
96	Preclinical AD predicts decline in memory and executive functions in subjective complaints. <i>Neurology</i> , 2013, 81, 1409-1416.	1.5	122
97	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). <i>Neurology</i> , 2015, 84, 508-515.	1.5	122
98	Diagnostic Imaging of Patients in a Memory Clinic: Comparison of MR Imaging and 64â€“Detector Row CT. <i>Radiology</i> , 2009, 253, 174-183.	3.6	121
99	CSF biomarker levels in early and late onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 1895-1901.	1.5	121
100	Detection of Alzheimer Pathology In Vivo Using Both <sup>11</sup> C-PIB and <sup>18</sup> F-FDDNP PET. <i>Journal of Nuclear Medicine</i> , 2009, 50, 191-197.	2.8	119
101	MRI Biomarkers of Vascular Damage and Atrophy Predicting Mortality in a Memory Clinic Population. <i>Stroke</i> , 2009, 40, 492-498.	1.0	118
102	Incidence of cerebral microbleeds. <i>Neurology</i> , 2010, 74, 1954-1960.	1.5	115
103	Longitudinal changes of CSF biomarkers in memory clinic patients. <i>Neurology</i> , 2007, 69, 1006-1011.	1.5	114
104	Prediction of Alzheimer disease in subjects with amnesic and nonamnesic MCI. <i>Neurology</i> , 2013, 80, 1124-1132.	1.5	110
105	Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study. <i>Journal of Neurology</i> , 2006, 253, 1189-1196.	1.8	109
106	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. <i>Brain</i> , 2012, 135, 2115-2125.	3.7	109
107	Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 801-807.	1.2	109
108	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015, 138, 2701-2715.	3.7	109

#	ARTICLE	IF	CITATIONS
109	Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers. <i>Human Brain Mapping</i> , 2014, 35, 2383-2393.	1.9	108
110	The Contribution of Medial Temporal Lobe Atrophy and Vascular Pathology to Cognitive Impairment in Vascular Dementia. <i>Stroke</i> , 2007, 38, 3182-3185.	1.0	107
111	Single-Subject Grey Matter Graphs in Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e58921.	1.1	107
112	CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2008, 29, 669-675.	1.5	103
113	Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 547-551.	0.9	103
114	Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. <i>Neurology</i> , 2018, 90, e149-e156.	1.5	103
115	Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 478-483.	0.9	102
116	Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. <i>Molecular Psychiatry</i> , 2017, 22, 153-160.	4.1	102
117	Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. <i>European Journal of Human Genetics</i> , 2017, 25, 973-981.	1.4	102
118	Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. <i>Brain</i> , 2018, 141, 3443-3456.	3.7	102
119	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. <i>JAMA Neurology</i> , 2018, 75, 1062.	4.5	102
120	Most rapid cognitive decline in APOE $\epsilon$ 4 negative Alzheimer's disease with early onset. <i>Psychological Medicine</i> , 2009, 39, 1907-1911.	2.7	101
121	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 59.	3.0	101
122	Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 113-118.	0.9	100
123	Differential effect of APOE $\epsilon$ genotype on amyloid load and glucose metabolism in AD dementia. <i>Neurology</i> , 2013, 80, 359-365.	1.5	99
124	Cerebral perfusion in the prodementia stages of Alzheimer's disease. <i>European Radiology</i> , 2016, 26, 506-514.	2.3	99
125	Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 531-540.	0.4	99
126	Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 2.	3.0	98



#	ARTICLE	IF	CITATIONS
127	Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations. <i>Neuropsychology Review</i> , 2017, 27, 245-257.	2.5	97
128	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. <i>European Radiology</i> , 2017, 27, 1169-1175.	2.3	97
129	ATN classification and clinical progression in subjective cognitive decline. <i>Neurology</i> , 2020, 95, e46-e58.	1.5	97
130	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
131	Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1497-1500.	0.9	96
132	CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. <i>Neurology</i> , 2009, 72, 1056-1061.	1.5	96
133	Whole-brain atrophy rate in Alzheimer disease. <i>Neurology</i> , 2008, 70, 1836-1841.	1.5	94
134	Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. <i>Neurology</i> , 2018, 90, e1231-e1239.	1.5	94
135	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 5.	3.0	94
136	Alzheimer's disease first symptoms are age dependent: Evidence from the NACC dataset. <i>Alzheimer's and Dementia</i> , 2015, 11, 1349-1357.	0.4	93
137	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 862-871.	0.4	93
138	Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. <i>Neurology</i> , 2001, 57, 2117-2120.	1.5	91
139	Neuroimaging and Correlates of Cognitive Function among Patients with Heart Failure. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 418-423.	0.7	91
140	Global dynamical analysis of the EEG in Alzheimer's disease: Frequency-specific changes of functional interactions. <i>Clinical Neurophysiology</i> , 2008, 119, 837-841.	0.7	91
141	EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. <i>Neurobiology of Aging</i> , 2017, 57, 133-142.	1.5	91
142	Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. <i>Neurobiology of Aging</i> , 2010, 31, 758-764.	1.5	90
143	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 235-243.	0.9	89
144	Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. <i>Diabetic Medicine</i> , 2007, 24, 166-171.	1.2	88

#	ARTICLE	IF	CITATIONS
145	Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. <i>European Radiology</i> , 2009, 19, 2826-2833.	2.3	88
146	White Matter Lesion Progression in LADIS. <i>Stroke</i> , 2012, 43, 2643-2647.	1.0	88
147	Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 425-432.	0.9	88
148	CSF $\beta$ -Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 87-95.	1.2	87
149	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 76.	3.0	87
150	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250.	3.9	87
151	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 198.	3.0	87
152	The effect of APOE genotype on clinical phenotype in Alzheimer disease. <i>Neurology</i> , 2006, 67, 526-527.	1.5	85
153	Disruption of Functional Brain Networks in Alzheimer's Disease: What Can We Learn from Graph Spectral Analysis of Resting-State Magnetoencephalography?. <i>Brain Connectivity</i> , 2012, 2, 45-55.	0.8	85
154	Relationship between progression of brain white matter changes and late-life depression: 3-year results from the LADIS study. <i>British Journal of Psychiatry</i> , 2012, 201, 40-45.	1.7	85
155	Trajectories of cognitive decline in different types of dementia. <i>Psychological Medicine</i> , 2015, 45, 1051-1059.	2.7	85
156	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	4.9	85
157	Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e87-e95.	2.0	85
158	The blood brain barrier in Alzheimer's disease. <i>Vascular Pharmacology</i> , 2017, 89, 12-18.	1.0	84
159	Early-Onset Dementia Is Associated with Higher Mortality. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 147-152.	0.7	82
160	Diffusion-Weighted Imaging and Cognition in the Leukoariosis and Disability in the Elderly Study. <i>Stroke</i> , 2010, 41, e402-8.	1.0	82
161	Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 505-512.	1.2	81
162	Neurological Signs in Relation to Type of Cerebrovascular Disease in Vascular Dementia. <i>Stroke</i> , 2008, 39, 317-322.	1.0	80

#	ARTICLE	IF	CITATIONS
163	Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?. <i>European Radiology</i> , 2015, 25, 3050-3059.	2.3	80
164	Reliability and Sensitivity of Visual Scales versus Volumetry for Evaluating White Matter Hyperintensity Progression. <i>Cerebrovascular Diseases</i> , 2008, 25, 247-253.	0.8	79
165	Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. <i>Radiology</i> , 2016, 279, 838-848.	3.6	79
166	α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. <i>Movement Disorders</i> , 2018, 33, 1724-1733.	2.2	79
167	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , 2016, 38, 214.e7-214.e10.	1.5	78
168	Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. <i>Neurology</i> , 2007, 69, 1491-1497.	1.5	77
169	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 287-295.	1.2	77
170	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. <i>JAMA Neurology</i> , 2017, 74, 1481.	4.5	77
171	On the Etiology of Incident Brain Lacunes. <i>Stroke</i> , 2008, 39, 3083-3085.	1.0	76
172	Alzheimer's disease: The state of the art in resting-state magnetoencephalography. <i>Clinical Neurophysiology</i> , 2017, 128, 1426-1437.	0.7	76
173	A clinical-radiological framework of the right temporal variant of frontotemporal dementia. <i>Brain</i> , 2020, 143, 2831-2843.	3.7	76
174	Interaction of medial temporal lobe atrophy and white matter hyperintensities in AD. <i>Neurology</i> , 2004, 62, 1862-1864.	1.5	75
175	BACE1 Activity in Cerebrospinal Fluid and Its Relation to Markers of AD Pathology. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 253-260.	1.2	75
176	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. <i>Neurobiology of Aging</i> , 2012, 33, 2272-2281.	1.5	75
177	Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimer's Disease. An MEG Study with Virtual Electrodes. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 238.	1.0	75
178	Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 319-327.	1.2	73
179	White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. <i>Stroke</i> , 2015, 46, 2661-2664.	1.0	73
180	The use of EEG in the diagnosis of dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 377-380.	0.9	72

#	ARTICLE	IF	CITATIONS
181	Cerebral Blood Flow by Using Pulsed Arterial Spin-Labeling in Elderly Subjects with White Matter Hyperintensities. <i>American Journal of Neuroradiology</i> , 2008, 29, 1296-1301.	1.2	72
182	Microbleeds do not affect rate of cognitive decline in Alzheimer disease. <i>Neurology</i> , 2012, 79, 763-769.	1.5	72
183	Increased Number of Microinfarcts in Alzheimer Disease at 7-T MR Imaging. <i>Radiology</i> , 2014, 270, 205-211.	3.6	72
184	Prevalence of cortical superficial siderosis in a memory clinic population. <i>Neurology</i> , 2014, 82, 698-704.	1.5	71
185	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 711-720.	1.2	71
186	MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 117.	1.7	71
187	Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. <i>Neurology</i> , 2009, 73, 935-940.	1.5	70
188	Single-Subject Gray Matter Graph Properties and Their Relationship with Cognitive Impairment in Early- and Late-Onset Alzheimer's Disease. <i>Brain Connectivity</i> , 2014, 4, 337-346.	0.8	69
189	Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, 846-854.	1.7	69
190	Magnetic Resonance Imaging Predictors of Cognition in Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 1023.	4.9	67
191	Cognitive Impairment in Alzheimer's Disease Is Modified by APOE Genotype. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 98-103.	0.7	66
192	Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2488-2494.	1.5	66
193	The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 27.	3.0	66
194	Loss of EEG network Efficiency Related to Cognitive Impairment in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2015, 30, 1785-1793.	2.2	65
195	Resting state functional connectivity differences between behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 474.	1.0	64
196	The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 27.	3.0	63
197	Cognitive decline in AD and mild cognitive impairment is associated with global brain damage. <i>Neurology</i> , 2002, 59, 874-879.	1.5	62
198	Prognostic Factors for Cognitive Decline After Intracerebral Hemorrhage. <i>Stroke</i> , 2015, 46, 2773-2778.	1.0	61

#	ARTICLE	IF	CITATIONS
199	Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic Cohort: The SABRE Study. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 279.	1.7	61
200	Prevalence and Clinical Significance of Epileptiform EEG Discharges in a Large Memory Clinic Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 432-437.	0.7	60
201	Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 687-697.	1.2	60
202	Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic. <i>Alzheimer's and Dementia</i> , 2015, 11, 523-532.	0.4	59
203	Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. <i>Alzheimer's and Dementia</i> , 2017, 13, 1226-1236.	0.4	59
204	A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. <i>Human Brain Mapping</i> , 2017, 38, 4703-4715.	1.9	59
205	Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. <i>Radiology</i> , 2016, 281, 865-875.	3.6	58
206	Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\beta$ 2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.4	58
207	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. <i>Brain</i> , 2016, 139, 2528-2539.	3.7	58
208	Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort. <i>Journal of the Neurological Sciences</i> , 2011, 307, 100-105.	0.3	57
209	The Dutch Parelinoer Institute - Neurodegenerative diseases; methods, design and baseline results. <i>BMC Neurology</i> , 2014, 14, 254.	0.8	57
210	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 143-151.	1.2	57
211	Associations between Patterns of EEG Abnormalities and Diagnosis in a Large Memory Clinic Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 18-23.	0.7	56
212	Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 882-884.	0.9	56
213	Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e102995.	1.1	56
214	Blood-based metabolic signatures in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 196-207.	1.2	56
215	Small vessel versus large vessel vascular dementia. <i>Journal of Neurology</i> , 2008, 255, 1644-1651.	1.8	55
216	Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1011.e1-1011.e9.	1.5	55

#	ARTICLE	IF	CITATIONS
217	Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 1103-1110.	1.2	55
218	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , 2020, 95, e1538-e1553.	1.5	55
219	Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. <i>Neurobiology of Aging</i> , 2012, 33, 1591-1598.	1.5	52
220	EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer's disease and controls. <i>Neurobiology of Aging</i> , 2016, 41, 122-129.	1.5	52
221	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 61, 75-81.	1.5	52
222	Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 563-572.	1.2	52
223	Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline. <i>Frontiers in Psychiatry</i> , 2020, 11, 585686.	1.3	52
224	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. <i>Neurology</i> , 2014, 82, 1768-1775.	1.5	51
225	Gray matter network disruptions and amyloid beta in cognitively normal adults. <i>Neurobiology of Aging</i> , 2016, 37, 154-160.	1.5	51
226	Applying the ATN scheme in a memory clinic population. <i>Neurology</i> , 2019, 93, e1635-e1646.	1.5	51
227	Diagnostic Value of the CSF $\pm$ -Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies. <i>Neurology</i> , 2021, 97, e930-e940.	1.5	51
228	Distinct perfusion patterns in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies. <i>European Radiology</i> , 2014, 24, 2326-2333.	2.3	50
229	Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2016, 12, 872-881.	0.4	50
230	Late-Onset Dementia: Structural Brain Damage and Total Cerebral Blood Flow. <i>Radiology</i> , 2005, 236, 990-995.	3.6	49
231	Apolipoprotein E Genotype Influences Presence and Severity of Delusions and Aggressive Behavior in Alzheimer Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 42-46.	0.7	49
232	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2340-2347.	1.5	49
233	PLD3 variants in population studies. <i>Nature</i> , 2015, 520, E2-E3.	13.7	49
234	Highly specific and ultrasensitive plasma test detects Abeta(1 $\beta$ 42) and Abeta(1 $\beta$ 40) in Alzheimer's disease. <i>Scientific Reports</i> , 2021, 11, 9736.	1.6	49

#	ARTICLE	IF	CITATIONS
235	New Research Criteria for the Diagnosis of Alzheimer's Disease Applied in a Memory Clinic Population. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 1-7.	0.7	48
236	Microbleeds, Mortality, and Stroke in Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 539.	4.5	48
237	A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 521-537.	1.2	48
238	Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Human Brain Mapping</i> , 2016, 37, 978-988.	1.9	48
239	Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE $\epsilon$ 4 genotype. <i>Neurology</i> , 2020, 95, e2378-e2388.	1.5	48
240	Microbleeds in vascular dementia: Clinical aspects. <i>Experimental Gerontology</i> , 2012, 47, 853-857.	1.2	47
241	Patients' and caregivers' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 314-322.	1.8	47
242	Investigation of resting-state EEG functional connectivity in frontotemporal lobar degeneration. <i>Clinical Neurophysiology</i> , 2008, 119, 1732-1738.	0.7	46
243	More Atrophy of Deep Gray Matter Structures in Frontotemporal Dementia Compared to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 635-647.	1.2	46
244	Clinical phenotype, atrophy, and small vessel disease in APOE $\epsilon$ 2 carriers with Alzheimer disease. <i>Neurology</i> , 2018, 91, e1851-e1859.	1.5	46
245	Centenarian controls increase variant effect sizes by an average twofold in an extreme case "extreme control analysis of Alzheimer's disease. <i>European Journal of Human Genetics</i> , 2019, 27, 244-253.	1.4	46
246	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. <i>Molecular Neurodegeneration</i> , 2020, 15, 36.	4.4	46
247	Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods. <i>Neurology</i> , 2021, 97, 474-488.	1.5	46
248	Comparison of the Alzheimer's Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in Differentiating Elderly Individuals with Different Degrees of White Matter Changes. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 73-81.	0.7	45
249	CSF Biomarkers in Alzheimer's Disease and Controls: Associations with APOE Genotype are Modified by Age. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 601-607.	1.2	45
250	Differential association of [ <sup>11</sup> C]PIB and [ <sup>18</sup> F]FDDNP binding with cognitive impairment. <i>Neurology</i> , 2009, 73, 2079-2085.	1.5	45
251	SUCLG2 identified as both a determinant of CSF A $\beta$ 42 levels and an attenuator of cognitive decline in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014, 23, 6644-6658.	1.4	45
252	The Heart-Brain Connection: A Multidisciplinary Approach Targeting a Missing Link in the Pathophysiology of Vascular Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S443-S451.	1.2	45

#	ARTICLE	IF	CITATIONS
253	Subjective Memory Complaints in APOE $\epsilon$ 4 Carriers are Associated with High Amyloid- $\beta$ Burden. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 1115-1122.	1.2	45
254	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 13333.	1.6	45
255	The Missing Link in the Pathophysiology of Vascular Cognitive Impairment: Design of the Heart-Brain Study. <i>Cerebrovascular Diseases Extra</i> , 2018, 7, 140-152.	0.5	44
256	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2018, 61, 198-206.	1.5	44
257	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, 1189-1204.	0.4	44
258	Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum. <i>Neurology</i> , 2021, 97, e1276-e1287.	1.5	44
259	Early onset APOE E4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains. <i>European Neuropsychopharmacology</i> , 2015, 25, 1010-1017.	0.3	43
260	7T T2*-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 20-26.	1.5	43
261	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 101.	3.0	43
262	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. <i>Alzheimer's and Dementia</i> , 2020, 16, 1457-1468.	0.4	43
263	EEG abnormalities in early and late onset Alzheimer's disease: understanding heterogeneity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 67-71.	0.9	42
264	Serum Leptin is not Altered nor Related to Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 809-813.	1.2	42
265	Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 43-52.	1.2	42
266	Quantification of Tau Load Using [18F]AV1451 PET. <i>Molecular Imaging and Biology</i> , 2017, 19, 963-971.	1.3	42
267	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. <i>Neurobiology of Aging</i> , 2019, 84, 225-234.	1.5	42
268	Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2021, 31, 102712.	1.4	42
269	Transcranial Doppler Blood Flow Assessment in Patients With Mild Heart Failure: Correlates With Neuroimaging and Cognitive Performance. <i>Congestive Heart Failure</i> , 2008, 14, 61-65.	2.0	41
270	Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 927-943.	1.2	41



#	ARTICLE	IF	CITATIONS
271	Long-Term Prognostic Implications of Previous Silent Myocardial Infarction in Patients Presenting With Acute Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1773-1781.	2.3	41
272	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 463-472.	1.1	41
273	Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCE project. <i>Neurobiology of Aging</i> , 2019, 79, 50-58.	1.5	41
274	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. <i>Neurology</i> , 2022, 98, .	1.5	41
275	Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 38, 21-31.	1.5	40
276	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. <i>Human Brain Mapping</i> , 2018, 39, 3143-3151.	1.9	40
277	Discordant amyloid- $\beta$ PET and CSF biomarkers and its clinical consequences. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 78.	3.0	40
278	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. <i>Acta Neuropathologica</i> , 2020, 139, 1025-1044.	3.9	40
279	Spatial-Temporal Patterns of $\beta$ -Amyloid Accumulation. <i>Neurology</i> , 2022, 98, .	1.5	40
280	Additional Value of CSF Amyloid- $\beta$ 40 Levels in the Differentiation between FTLN and Control Subjects. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 445-452.	1.2	39
281	Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 76-83.	1.2	39
282	A $\beta$ 34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. <i>Nature Communications</i> , 2019, 10, 2240.	5.8	39
283	Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 491-497.	0.7	38
284	Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study. <i>NeuroImage: Clinical</i> , 2015, 9, 418-429.	1.4	38
285	Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset. <i>Scientific Reports</i> , 2019, 9, 16742.	1.6	38
286	Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease. <i>JMIR Formative Research</i> , 2019, 3, e13417.	0.7	38
287	Amyloid and its association with default network integrity in Alzheimer's disease. <i>Human Brain Mapping</i> , 2014, 35, 779-791.	1.9	37
288	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 46, 235.e1-235.e9.	1.5	37

#	ARTICLE	IF	CITATIONS
289	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , 2018, 64, 927-937.	1.5	37
290	Amyloid- $\beta^2$ Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCE Project. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 7.	1.7	37
291	Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. <i>Neurology</i> , 2021, 96, e2673-e2684.	1.5	37
292	The Added Value of 18-Fluorodeoxyglucose-Positron Emission Tomography in the Diagnosis of the Behavioral Variant of Frontotemporal Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2014, 29, 607-613.	0.9	36
293	The Rest-Activity Rhythm and Physical Activity in Early-Onset Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 45-49.	0.6	36
294	Web-Based Multidomain Lifestyle Programs for Brain Health: Comprehensive Overview and Meta-Analysis. <i>JMIR Mental Health</i> , 2019, 6, e12104.	1.7	36
295	Distribution of APOE Genotypes in a Memory Clinic Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 433-438.	0.7	35
296	Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 243-252.	1.2	35
297	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 581-590.	1.2	35
298	Detecting frontotemporal dementia syndromes using MRI biomarkers. <i>NeuroImage: Clinical</i> , 2019, 22, 101711.	1.4	35
299	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services" part 2 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 169.	3.0	35
300	Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 387-392.	1.3	34
301	Young Alzheimer patients show distinct regional changes of oscillatory brain dynamics. <i>Neurobiology of Aging</i> , 2012, 33, 1008.e25-1008.e31.	1.5	34
302	Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study. <i>Journal of Neurology</i> , 2013, 260, 1014-1021.	1.8	34
303	The Influence of Co-Morbidity and Frailty on the Clinical Manifestation of Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 501-509.	1.2	34
304	The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 959-975.	1.2	34
305	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 72.	3.0	34
306	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCE project. <i>Neurobiology of Aging</i> , 2020, 89, 99-107.	1.5	34

#	ARTICLE	IF	CITATIONS
307	MRI measures and progression of cognitive decline in nondemented elderly attending a memory clinic. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 1060-1066.	1.3	33
308	Quantitation of brain tissue changes associated with white matter hyperintensities by diffusion-weighted and magnetization transfer imaging: The LADIS (leukoaraiosis and disability in the Tj ETQq0 010rgBT /Overlock 10	1.0	32
309	Apraxia in Mild Cognitive Impairment and Alzheimer's Disease: Validity and Reliability of the Van Heugten Test for Apraxia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 55-64.	0.7	33
310	Directional information flow in patients with Alzheimer's disease. A source-space resting-state MEG study. <i>NeuroImage: Clinical</i> , 2017, 15, 673-681.	1.4	33
311	Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1827-1839.	1.2	33
312	Gray matter T1w/T2w ratios are higher in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 3900-3909.	1.9	33
313	Immune response and endocytosis pathways are associated with the resilience against Alzheimer's disease. <i>Translational Psychiatry</i> , 2020, 10, 332.	2.4	33
314	The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 735-744.	0.6	33
315	Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression. <i>Movement Disorders</i> , 2020, 35, 859-867.	2.2	33
316	Validation of the automated method VIENA: An accurate, precise, and robust measure of ventricular enlargement. <i>Human Brain Mapping</i> , 2014, 35, 1101-1110.	1.9	32
317	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. <i>Alzheimer's and Dementia</i> , 2017, 13, 903-912.	0.4	32
318	Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer's Disease in a Family with Several Generations of APOE-É4 Homozygosity. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 63-74.	1.2	32
319	Infratentorial Abnormalities in Vascular Dementia. <i>Stroke</i> , 2006, 37, 105-110.	1.0	31
320	Structural neuroimaging. , 2009, , 58-69.		31
321	Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, S299-305.	0.4	31
322	Malnutrition and Risk of Structural Brain Changes Seen on Magnetic Resonance Imaging in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 2457-2463.	1.3	31
323	Dietary patterns are related to cognitive functioning in elderly enriched with individuals at increased risk for Alzheimer's disease. <i>European Journal of Nutrition</i> , 2021, 60, 849-860.	1.8	31
324	Amyloid-É2 misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 169.	3.0	31

#	ARTICLE	IF	CITATIONS
325	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	4.5	31
326	Joint Effect of Hypertension and <i>APOE</i> Genotype on CSF Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1083-1090.	1.2	30
327	Building a New Paradigm for the Early Recognition of Behavioral Variant Frontotemporal Dementia: Late Onset Frontal Lobe Syndrome Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 735-740.	0.6	30
328	Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 389-397.	1.2	30
329	Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 33.	3.0	30
330	Brain amyloid $\beta$ , cerebral small vessel disease, and cognition. <i>Neurology</i> , 2020, 95, e2845-e2853.	1.5	30
331	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 426-438.	1.2	30
332	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 111.	1.7	29
333	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 67.	1.7	29
334	Frequent Cognitive Impairment in Patients With Disorders Along the Heart-Brain Axis. <i>Stroke</i> , 2019, 50, 3369-3375.	1.0	29
335	Regional [ $^{18}$ F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2866-2878.	3.3	29
336	Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment (TRACE-VCI) Study. <i>JMIR Research Protocols</i> , 2017, 6, e60.	0.5	29
337	Magnetization transfer imaging of gray and white matter in mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1757-1762.	1.5	28
338	Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2665-2670.	1.5	28
339	Diagnostic dilemmas in Alzheimer's disease: Room for shared decision making. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 301-304.	1.8	28
340	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [ $^{18}$ F]-Flutemetamol PET Scan Result. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 409.	1.7	28
341	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease—Data from three memory clinic studies. <i>Alzheimer's and Dementia</i> , 2019, 15, 185-193.	0.4	28
342	Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3165-3175.	3.3	28

#	ARTICLE	IF	CITATIONS
343	Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	28
344	Neuropsychological Correlates of MRI Measures in the Continuum of Cognitive Decline at Old Age. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 82-88.	0.7	27
345	Shifting Paradigms in Dementia: Toward Stratification of Diagnosis and Treatment Using MRI. <i>Annals of the New York Academy of Sciences</i> , 2007, 1097, 215-224.	1.8	27
346	Serum Amyloid P Component as a Biomarker in Mild Cognitive Impairment and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 522-527.	0.7	27
347	Quantitative regional validation of the visual rating scale for posterior cortical atrophy. <i>European Radiology</i> , 2014, 24, 397-404.	2.3	27
348	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1605.e13-1605.e20.	1.5	27
349	Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 309-320.	1.2	27
350	Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101786.	1.4	27
351	Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 638-651.	1.9	27
352	EEG functional connectivity and ApoE genotype in Alzheimer's disease and controls. <i>Clinical Neurophysiology</i> , 2008, 119, 2727-2732.	0.7	26
353	Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 1056-1066.	0.6	26
354	CSF ApoE predicts clinical progression in nondemented APOE $\epsilon$ 4 carriers. <i>Neurobiology of Aging</i> , 2017, 57, 186-194.	1.5	26
355	VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4674.	1.8	26
356	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 168.	3.0	26
357	Neuropsychological Predictors of Dementia in a Three-Year Follow-Up Period: Data from the LADIS Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 325-334.	0.7	25
358	Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. <i>Alzheimer's and Dementia</i> , 2013, 9, 276-283.	0.4	25
359	Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology. <i>Acta Neuropathologica Communications</i> , 2014, 2, 79.	2.4	25
360	The structure of the geriatric depressed brain and response to electroconvulsive therapy. <i>Psychiatry Research - Neuroimaging</i> , 2014, 222, 1-9.	0.9	25

#	ARTICLE	IF	CITATIONS
361	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 73.	3.0	25
362	Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project. <i>Nutrients</i> , 2019, 11, 1161.	1.7	25
363	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1585-1595.	1.2	25
364	Contribution of Gut Microbiota to Immunological Changes in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2021, 12, 683068.	2.2	25
365	Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 31.	3.0	25
366	Episodic memory and the medial temporal lobe: not all it seems. Evidence from the temporal variants of frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1145-1148.	0.9	24
367	Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia. <i>BMC Neuroscience</i> , 2012, 13, 85.	0.8	24
368	Comparison of Simplified Parametric Methods for Visual Interpretation of <sup>11</sup> C-Pittsburgh Compound-B PET Images. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1305-1307.	2.8	24
369	Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. <i>Neurology</i> , 2019, 92, e1558-e1566.	1.5	24
370	Clinicians' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 305-313.	1.8	23
371	Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. <i>Neurobiology of Aging</i> , 2018, 61, 238-244.	1.5	23
372	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2018, 19, 625-632.	1.4	23
373	Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1037-1047.	1.7	23
374	Clinician-patient communication during the diagnostic workup: The ABIDE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 520-528.	1.2	23
375	Amyloid- $\beta$ peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 83.	3.0	23
376	Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 25.	3.0	23
377	Automatically computed rating scales from MRI for patients with cognitive disorders. <i>European Radiology</i> , 2019, 29, 4937-4947.	2.3	23
378	Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. <i>Current Alzheimer Research</i> , 2019, 16, 91-101.	0.7	23

#	ARTICLE	IF	CITATIONS
379	Testâ€“retest repeatability of [ <sup>18</sup> F]Flortaucipir PET in Alzheimerâ€™s disease and cognitively normal individuals. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 2464-2474.	2.4	23
380	Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 44.	3.0	23
381	The natural history of primary progressive aphasia: beyond aphasia. <i>Journal of Neurology</i> , 2022, 269, 1375-1385.	1.8	23
382	Hippocampal volume loss and Alzheimer disease progression. <i>Nature Reviews Neurology</i> , 2009, 5, 361-362.	4.9	22
383	A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2013, 9, 262-268.	0.4	22
384	Survival in memory clinic cohort is short, even in young-onset dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 726-728.	0.9	22
385	Quantification of [ <sup>18</sup> F]florbetapir: A testâ€“retest tracer kinetic modelling study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2172-2180.	2.4	22
386	High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. <i>Neuropsychologia</i> , 2019, 131, 184-192.	0.7	22
387	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.4	22
388	Evaluation of Intrathecal Serum Amyloid P (SAP) and C-Reactive Protein (CRP) Synthesis in Alzheimer's Disease with the Use of Index Values. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1073-1079.	1.2	21
389	EEG Abnormalities Are Associated with Different Cognitive Profiles in Alzheimerâ€™s Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 1-6.	0.7	21
390	Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 61-5.	1.4	21
391	Associations between Magnetic Resonance Imaging Measures and Neuropsychological Impairment in Early and Late Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 169-178.	1.2	21
392	Predictors of Progression from Mild Cognitive Impairment to Dementia in the Placebo-Arm of a Clinical Trial Population. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 79-85.	1.2	21
393	Progression to dementia in memory clinic patients without dementia. <i>Neurology</i> , 2013, 81, 1342-1349.	1.5	21
394	Hypertensive Disorders of Pregnancy Appear Not to Be Associated with Alzheimer's Disease Later in Life. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 375-385.	0.6	21
395	Clinical heterogeneity in familial Alzheimerâ€™s disease. <i>Lancet Neurology</i> , The, 2016, 15, 1296-1298.	4.9	21
396	Effect of long-term storage in biobanks on cerebrospinal fluid biomarker A $\beta$ <sub>1-42</sub> , T $\tau$ , and P $\tau$ values. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 45-50.	1.2	21

#	ARTICLE	IF	CITATIONS
397	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 58.	3.0	21
398	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. <i>Journal of Psychiatric Research</i> , 2018, 104, 183-191.	1.5	21
399	PET and CSF amyloid- $\beta^2$ status are differently predicted by patient features: information from discordant cases. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 100.	3.0	21
400	Olfactory and gustatory functioning and food preferences of patients with Alzheimer's disease and mild cognitive impairment compared to controls: the NUDAD project. <i>Journal of Neurology</i> , 2020, 267, 144-152.	1.8	21
401	A Suboptimal Diet Is Associated with Poorer Cognition: The NUDAD Project. <i>Nutrients</i> , 2020, 12, 703.	1.7	21
402	Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEVELOP design and baseline results. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 53.	3.0	21
403	Dementia risk communication. A user manual for Brain Health Services" part 3 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 170.	3.0	21
404	Lobar Distribution of Changes in Gray Matter and White Matter in Memory Clinic Patients: Detected Using Magnetization Transfer Imaging. <i>American Journal of Neuroradiology</i> , 2007, 28, 1938-1942.	1.2	20
405	Disturbed phase relations in white matter hyperintensity based vascular dementia: An EEG directed connectivity study. <i>Clinical Neurophysiology</i> , 2015, 126, 497-504.	0.7	20
406	Low normal cerebrospinal fluid A $\beta$ 242 levels predict clinical progression in nondemented subjects. <i>Annals of Neurology</i> , 2017, 81, 749-753.	2.8	20
407	Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 23.	3.0	20
408	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. <i>Alzheimer's and Dementia</i> , 2018, 14, 837-842.	0.4	20
409	Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 631-642.	1.2	20
410	Communicating uncertainties when disclosing diagnostic test results for (Alzheimer's) dementia in the memory clinic: The ABIDE project. <i>Health Expectations</i> , 2020, 23, 52-62.	1.1	20
411	Polygenic Risk Score of Longevity Predicts Longer Survival Across an Age Continuum. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 750-759.	1.7	20
412	Clinical Characteristics of Patients With Frontotemporal Dementia With and Without Lobar Atrophy on MRI. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 242-247.	0.6	19
413	Alzheimer's disease patients not carrying the apolipoprotein E $\epsilon$ 4 allele show more severe slowing of oscillatory brain activity. <i>Neurobiology of Aging</i> , 2013, 34, 2158-2163.	1.5	19
414	Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. , 2013, 9, 269-275.		19



#	ARTICLE	IF	CITATIONS
415	Increase in Cerebrospinal Fluid F2-Isoprostanes is Related to Cognitive Decline in APOE $\epsilon$ 4 Carriers. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 563-570.	1.2	19
416	The metabolic syndrome in a memory clinic population: Relation with clinical profile and prognosis. <i>Journal of the Neurological Sciences</i> , 2015, 351, 18-23.	0.3	19
417	Pseudo-healthy Image Synthesis for White Matter Lesion Segmentation. <i>Lecture Notes in Computer Science</i> , 2016, , 87-96.	1.0	19
418	Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 139-146.	1.2	19
419	Evaluating combinations of diagnostic tests to discriminate different dementia types. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 509-518.	1.2	19
420	Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. <i>Neurology</i> , 2020, 95, e1672-e1685.	1.5	19
421	Clinicians's communication with patients receiving a MCI diagnosis: The ABIDE project. <i>PLoS ONE</i> , 2020, 15, e0227282.	1.1	19
422	Plasma amyloid- $\beta$ oligomerization assay as a pre-screening test for amyloid status. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 133.	3.0	19
423	No Evidence for Additional Blood-Brain Barrier P-Glycoprotein Dysfunction in Alzheimer's Disease Patients with Microbleeds. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1468-1471.	2.4	18
424	Clinical aspects of microbleeds in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2012, 322, 56-58.	0.3	18
425	Angiotensin-Converting Enzyme in Cerebrospinal Fluid and Risk of Brain Atrophy. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 153-162.	1.2	18
426	Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 249-259.	1.2	18
427	Time Trend in Persistent Cognitive Decline: Results From the Longitudinal Aging Study Amsterdam. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2018, 73, S57-S64.	2.4	18
428	Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 52.	3.0	18
429	Orthostatic Hypotension: An Important Risk Factor for Clinical Progression to Mild Cognitive Impairment or Dementia. <i>The Amsterdam Dementia Cohort. Journal of Alzheimer's Disease</i> , 2019, 71, 317-325.	1.2	18
430	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1458-1467.	0.4	18
431	Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: the NUDAD project. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 116.	3.0	18
432	Hypertensive Exposure Markers by MRI in Relation to Cerebral Small Vessel Disease and Cognitive Impairment. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 176-185.	2.3	18

#	ARTICLE	IF	CITATIONS
433	Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 2.	3.0	18
434	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2157-2168.	3.3	18
435	Dysglycemia, brain volume and vascular lesions on MRI in a memory clinic population. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 85-90.	1.2	17
436	Actigraphic Motor Activity in Mild Cognitive Impairment Patients Carrying Out Short Functional Activity Tasks: Comparison between Mild Cognitive Impairment with and without Depressive Symptoms. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 869-875.	1.2	17
437	A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands. <i>BMC Neurology</i> , 2016, 16, 242.	0.8	17
438	Energy and Protein Intake of Alzheimer's Disease Patients Compared to Cognitively Normal Controls: Systematic Review. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 14-21.	1.2	17
439	Nature and implications of sex differences in AD pathology. <i>Nature Reviews Neurology</i> , 2019, 15, 6-8.	4.9	17
440	CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE $\epsilon$ 4 carriers. <i>Scientific Reports</i> , 2020, 10, 8233.	1.6	17
441	Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimer's Disease and Vascular Dementia. <i>Antioxidants</i> , 2020, 9, 456.	2.2	17
442	Circulating metabolites are associated with brain atrophy and white matter hyperintensities. <i>Alzheimer's and Dementia</i> , 2021, 17, 205-214.	0.4	17
443	Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1513.e1-1513.e17.	1.2	17
444	Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum. <i>Neurology</i> , 2022, 98, .	1.5	17
445	Usefulness of Longitudinal Measurements of $\beta$ -Amyloid $\beta$ 42 in Cerebrospinal Fluid of Patients with Various Cognitive and Neurologic Disorders. <i>Clinical Chemistry</i> , 2006, 52, 1604-1606.	1.5	16
446	Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 1300-4.	1.4	16
447	Translational Research in Genomics of Alzheimer's Disease: A Review of Current Practice and Future Perspectives. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 967-980.	1.2	16
448	Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study. <i>Journal of Neurology</i> , 2014, 261, 1160-1169.	1.8	16
449	White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid- $\beta$ . <i>Journal of Alzheimer's Disease</i> , 2016, 55, 333-342.	1.2	16
450	The Impact of Frailty and Comorbidity on Institutionalization and Mortality in Persons With Dementia: A Prospective Cohort Study. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 165-170.e2.	1.2	16

#	ARTICLE	IF	CITATIONS
451	ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 77.	3.0	16
452	The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 311-322.	1.2	16
453	Classification of negative and positive 18F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 721-728.	3.3	16
454	Risk of dementia in <i>APOE</i> $\epsilon$ 4 carriers is mitigated by a polygenic risk score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12229.	1.2	16
455	[ <sup>18</sup> F]Flortaucipir PET Across Various <i>MAPT</i> Mutations in Presymptomatic and Symptomatic Carriers. <i>Neurology</i> , 2021, 97, e1017-e1030.	1.5	16
456	Detection of contactin-2 in cerebrospinal fluid (CSF) of patients with Alzheimer's disease using Fluorescence Correlation Spectroscopy (FCS). <i>Clinical Biochemistry</i> , 2017, 50, 1061-1066.	0.8	16
457	Improving the Accuracy and Precision of Cognitive Testing in Mild Dementia. <i>Journal of the International Neuropsychological Society</i> , 2012, 18, 314-322.	1.2	15
458	Design of the ExCersion <sup>TM</sup> VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 157-165.	1.8	15
459	Cerebral blood flow and cognitive functioning in patients with disorders along the heart-brain axis. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12034.	1.8	15
460	Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis?. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12189.	1.8	15
461	Study protocol: EXERcise and Cognition In Sedentary adults with Early-ONset dementia (EXERCISE-ON). <i>BMC Neurology</i> , 2012, 12, 75.	0.8	14
462	Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 261-270.	1.2	14
463	Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1029-1039.	1.2	14
464	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 1-9.	1.2	14
465	Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies. <i>Biomolecules</i> , 2020, 10, 1177.	1.8	14
466	Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study. <i>NeuroImage: Clinical</i> , 2020, 28, 102504.	1.4	14
467	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 138.	3.0	14
468	Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia. <i>Archives of Neurology</i> , 2006, 63, 144.	4.9	14

#	ARTICLE	IF	CITATIONS
469	Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 94, 71-80.	1.5	14
470	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1061-1070.	1.2	13
471	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. <i>NeuroImage: Clinical</i> , 2021, 30, 102660.	1.4	13
472	The protective gene dose effect of the <i>APOE</i> $\epsilon 2$ allele on gray matter volume in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2022, 18, 1383-1395.	0.4	13
473	Carotid and Basilar Artery Wall Shear Stress in Alzheimer's Disease and Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 220-224.	0.7	12
474	Progression from MCI to AD: Predictive value of CSF $A\beta_{42}$ is modified by APOE genotype. <i>Neurobiology of Aging</i> , 2011, 32, 1372-1378.	1.5	12
475	Cortical phase changes measured using $7\text{T}$ MRI in subjects with subjective cognitive impairment, and their association with cognitive function. <i>NMR in Biomedicine</i> , 2016, 29, 1289-1294.	1.6	12
476	Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 41, 16-26.	0.7	12
477	Lumbar puncture in patients with neurologic conditions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 108-110.	1.2	12
478	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	1.5	12
479	ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF $A\beta_{42}$ , levels in non-demented elderly. <i>Neurobiology of Aging</i> , 2019, 79, 101-109.	1.5	12
480	Identifying a task-invariant cognitive reserve network using task potency. <i>NeuroImage</i> , 2020, 210, 116593.	2.1	12
481	Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 107, 1-10.	1.5	12
482	Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial. <i>Alzheimer's and Dementia</i> , 2023, 19, 285-295.	0.4	12
483	Use of laboratory and imaging investigations in dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, v45-v52.	0.9	11
484	Glycemia and Levels of Cerebrospinal Fluid Amyloid and Tau in Patients Attending a Memory Clinic. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 1318-1321.	1.3	11
485	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 889-899.	1.2	11
486	Standard biobanking conditions prevent evaporation of body fluid samples. <i>Clinica Chimica Acta</i> , 2015, 442, 141-145.	0.5	11

#	ARTICLE	IF	CITATIONS
487	Wishes and preferences for an online lifestyle program for brain health—A mixed methods study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 141-149.	1.8	11
488	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019, 266, 2535-2545.	1.8	11
489	ASSOCIATION BETWEEN VITAMIN B6 AND WHITE MATTER HYPERINTENSITIES IN PATIENTS WITH ALZHEIMER'S DISEASE NOT MEDIATED BY HOMOCYSTEINE METABOLISM. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 956-958.	1.3	10
490	Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort. <i>Journal of Neurology</i> , 2014, 261, 2085-2092.	1.8	10
491	Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCE Project. <i>Nutrients</i> , 2019, 11, 1057.	1.7	10
492	Methylphenidate and galantamine in patients with vascular cognitive impairment—the proof-of-principle study STREAM-VCI. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 10.	3.0	10
493	Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , 2023, 24, 638-644.e1.	1.2	10
494	Repeatability of parametric methods for [ <sup>18</sup> F]florbetapir imaging in Alzheimer's disease and healthy controls: A test-retest study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 569-578.	2.4	10
495	Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies. <i>Molecular Imaging and Biology</i> , 2021, 23, 604-613.	1.3	10
496	The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1195-1201.	1.2	10
497	Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 269-279.	1.2	10
498	Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. <i>Brain Communications</i> , 2020, 2, fcaa177.	1.5	10
499	Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. <i>Neurology</i> , 2022, 98, .	1.5	10
500	Cerebral atrophy in elderly with subjective memory complaints. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 358-364.	1.9	9
501	Pre-analytical stability of novel cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> , 2019, 497, 204-211.	0.5	9
502	Assessing the Pre-Analytical Stability of Small-Molecule Metabolites in Cerebrospinal Fluid Using Direct-Infusion Metabolomics. <i>Metabolites</i> , 2019, 9, 236.	1.3	9
503	cCOG: A web-based cognitive test tool for detecting neurodegenerative disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12083.	1.2	9
504	Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12063.	1.2	9

#	ARTICLE	IF	CITATIONS
505	Amyloid- $\beta^2$ , cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 348-358.	1.7	9
506	Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups. <i>NeuroImage: Clinical</i> , 2021, 31, 102725.	1.4	9
507	What patients want to know, and what we actually tell them: The ABIDE project. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12113.	1.8	9
508	Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion-symptom mapping study. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, E1-E10.	1.4	9
509	Computer-assisted prediction of clinical progression in the earliest stages of AD. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 726-736.	1.2	8
510	Added value of amyloid PET in individualized risk predictions for MCI patients. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 529-537.	1.2	8
511	Why Is Amyloid- $\beta^2$ PET Requested After Performing CSF Biomarkers?. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 559-569.	1.2	8
512	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 381-390.	1.2	8
513	Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1951-1963.	3.3	8
514	Frontal lobe damage and thalamic volume changes. <i>NeuroReport</i> , 2000, 11, 3039-3041.	0.6	7
515	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1190-8.	3.3	7
516	Combinations of Service Use Types of People With Early Cognitive Disorders. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 620-625.	1.2	7
517	Microbleeds are associated with depressive symptoms in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 112-120.	1.2	7
518	Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 73, 230.e9-230.e17.	1.5	7
519	Profound regional spectral, connectivity, and network changes reflect visual deficits in posterior cortical atrophy: an EEG study. <i>Neurobiology of Aging</i> , 2020, 96, 1-11.	1.5	7
520	Small vessel disease lesion type and brain atrophy: The role of co-occurring amyloid. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12060.	1.2	7
521	Non-memory cognitive symptom development in Alzheimer's disease. <i>European Journal of Neurology</i> , 2020, 27, 995-1002.	1.7	7
522	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. <i>PLoS ONE</i> , 2020, 15, e0226784.	1.1	7

#	ARTICLE	IF	CITATIONS
523	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12120.	1.2	7
524	Psychosocial Effects of COVID-19 Measures on (Pre-)Dementia Patients During Second Lockdown. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 931-939.	1.2	7
525	The Effect of Alzheimer's Disease-Associated Genetic Variants on Longevity. <i>Frontiers in Genetics</i> , 2021, 12, 748781.	1.1	7
526	Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease. <i>Neurology</i> , 2003, 60, 1558-1559.	1.5	6
527	The effect of APOE genotype on clinical phenotype in Alzheimer disease. <i>Neurology</i> , 2007, 68, 624-624.	1.5	6
528	Knowing the natural course of biomarkers in AD: Longitudinal MRI, CSF and PET data. <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 353-355.	1.5	6
529	Neurological Signs in Relation to White Matter Hyperintensity Volumes in Memory Clinic Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 301-308.	0.7	6
530	A novel <i>CCM2</i> variant in a family with non-progressive cognitive complaints and cerebral microbleeds. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017, 174, 220-226.	1.1	6
531	Comorbid amyloid $\beta$ pathology affects clinical and imaging features in VCD. <i>Alzheimer's and Dementia</i> , 2020, 16, 354-364.	0.4	6
532	Biomarker testing in MCI patients—deciding who to test. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 14.	3.0	6
533	Assessing the Views of Professionals, Patients, and Care Partners Concerning the Use of Computer Tools in Memory Clinics: International Survey Study. <i>JMIR Formative Research</i> , 2021, 5, e31053.	0.7	6
534	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. <i>Translational Psychiatry</i> , 2021, 11, 451.	2.4	6
535	BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCE project. <i>Neurobiology of Aging</i> , 2021, 108, 146-154.	1.5	6
536	Short Digital Spatial Memory Test Detects Impairment in Alzheimer's Disease and Mild Cognitive Impairment. <i>Brain Sciences</i> , 2021, 11, 1350.	1.1	6
537	Pre-Diagnostic Symptoms of Young-Onset Dementia in the General Practice up to Five Years Before Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 229-239.	1.2	6
538	Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 107-116.	1.2	5
539	P4-179: MEG Cross-Frequency Analysis in Patients With Alzheimer's Disease. , 2016, 12, P1087-P1088.		5
540	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 492-500.	1.8	5

#	ARTICLE	IF	CITATIONS
541	High occurrence of transportation and logistics occupations among vascular dementia patients: an observational study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 112.	3.0	5
542	Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. <i>NeuroImage: Clinical</i> , 2020, 25, 102113.	1.4	5
543	Prediction of poor clinical outcome in vascular cognitive impairment: TRACE-VCI study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12077.	1.2	5
544	Grey zone amyloid burden affects memory function: the SCIENCE project. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 747-756.	3.3	5
545	Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 22.	3.0	5
546	Subjective cognitive decline and self-reported sleep problems: The SCIENCE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	5
547	Design of the NL-NIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 233-240.	1.8	4
548	[O2-1203]: DURATION OF ALZHEIMER'S DISEASE IN THE PRECLINICAL, PRODROMAL AND DEMENTIA STAGE: A MULTISTATE MODEL ANALYSIS. <i>Alzheimer's and Dementia</i> , 2017, 13, P585.	0.4	4
549	How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1273-1286.	1.2	4
550	Everyday Functioning in a Community-Based Volunteer Population: Differences Between Participant- and Study Partner-Report. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 761932.	1.7	4
551	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline. <i>Brain Communications</i> , 2022, 4, fcac026.	1.5	4
552	Cerebrovascular disease in suspected non-Alzheimer's pathophysiology and cognitive decline over time. <i>European Journal of Neurology</i> , 2022, 29, 1922-1929.	1.7	4
553	Can lumbar puncture help to identify patients with incipient Alzheimer's disease?. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 530-531.	2.7	3
554	Prevalence and severity of microbleeds in a memory clinic setting. <i>Neurology</i> , 2007, 68, 391-391.	1.5	3
555	IC-P-013: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA. , 2014, 10, P14-P14.		3
556	P4-224: Alzheimer's Disease Patients With Osas History Have Higher CSF Tau Levels. <i>Alzheimer's and Dementia</i> , 2016, 12, P1115.	0.4	3
557	[P2-052]: THE DUTCH BRAIN HEALTH REGISTRY: OPTIMIZING RECRUITMENT FOR DEMENTIA RESEARCH. <i>Alzheimer's and Dementia</i> , 2017, 13, P624.	0.4	3
558	Reply to "Usefulness of Plasma Amyloid as Prescreener of the Earliest Alzheimer Pathological Changes Depends on the Study Population". <i>Annals of Neurology</i> , 2020, 87, 155-155.	2.8	3



#	ARTICLE	IF	CITATIONS
559	Using cerebrospinal fluid amyloid $\beta$ (1 $\beta$ 42) in the memory clinic: Concordance with PET and use of biomarker ratios across immunoassays. <i>Alzheimer's and Dementia</i> , 2020, 16, e045128.	0.4	3
560	The Cognitive Online Self $\beta$ Test Amsterdam (COST $\beta$ A): Establishing norm scores in a community $\beta$ dwelling population. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12234.	1.2	3
561	Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. <i>JMIR Research Protocols</i> , 2018, 7, e80.	0.5	3
562	A comparison of two approaches for modeling dementia progression in a changing patient context. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	3
563	Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer $\beta$ 's disease. <i>European Radiology</i> , 2022, 32, 7789-7799.	2.3	3
564	Hippocampal volume and cognition in geriatric depression. <i>Biological Psychiatry</i> , 2001, 50, 68-69.	0.7	2
565	IC-01-04: Diagnostic impact of [18 F]flutemetamol amyloid imaging in young-onset dementia. , 2015, 11, P3-P4.		2
566	F2-03-04: Genetic risk factors for posterior cortical atrophy. , 2015, 11, P168-P169.		2
567	[P1 $\beta$ 42]: ALPHA $\beta$ SYNUCLEIN SPECIES AS POTENTIAL CSF BIOMARKERS FOR DEMENTIA WITH LEWY BODIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P338.	0.4	2
568	[P1 $\beta$ 375]: DATA $\beta$ DRIVEN DIAGNOSIS OF DEMENTIA DISORDERS: THE PREDICTND VALIDATION STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P405.	0.4	2
569	IC $\beta$ P $\beta$ 192: DISEASE $\beta$ STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P158.	0.4	2
570	Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2020, 16, e041048.	0.4	2
571	Development of an ultrasensitive multiplex assay for simultaneous detection of A $\beta$ 1 $\beta$ 42, A $\beta$ 1 $\beta$ 40, GFAP and NF $\beta$ in blood. <i>Alzheimer's and Dementia</i> , 2020, 16, e043506.	0.4	2
572	The evolution of neuropsychiatric symptoms in atypical variants of Alzheimer $\beta$ 's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045236.	0.4	2
573	A mixed $\beta$ methods approach to establish clinically meaningful categories of impairment in instrumental activities of daily living. <i>Alzheimer's and Dementia</i> , 2020, 16, e045693.	0.4	2
574	Attitudes towards genetic susceptibility testing for Alzheimer $\beta$ 's disease dementia in cognitively normal adults: A survey study. <i>Alzheimer's and Dementia</i> , 2020, 16, e047393.	0.4	2
575	Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies. <i>Molecular Imaging and Biology</i> , 2021, 23, 550-559.	1.3	2
576	Sex and Cardiovascular Function in Relation to Vascular Brain Injury in Patients with Cognitive Complaints. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 261-271.	1.2	2

#	ARTICLE	IF	CITATIONS
577	Comparing a Single Clinician Versus a Multidisciplinary Consensus Conference Approach for Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 741-751.	1.2	2
578	A Semi-supervised Large Margin Algorithm for White Matter Hyperintensity Segmentation. <i>Lecture Notes in Computer Science</i> , 2016, , 104-112.	1.0	2
579	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers of AD progression: The NUDAD project. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.4	2
580	An Operational Definition of "Abnormal Cognition"™ to Optimize the Prediction of Progression to Dementia: What Are Optimal Cut-Off Points for Univariate and Multivariate Normative Comparisons?. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1693-1703.	1.2	2
581	Data-driven evidence for three distinct patterns of amyloid-β <sup>2</sup> accumulation. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
582	Study design of FINGER-NL: A multidomain lifestyle intervention in Dutch older adults to prevent cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
583	Does Loss of Integrity of the Cingulum Bundle Link Amyloid-β <sup>2</sup> Accumulation and Neurodegeneration in Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 39-49.	1.2	2
584	F5-01-02: CSF biomarkers and APOE genotype as predictors of clinical progression in patients with subjective complaints. , 2013, 9, P824-P824.		1
585	P1-258: CORTICAL PHASE CHANGES AT 7T MRI IN SUBJECTIVE COGNITIVE IMPAIRMENT AND THEIR ASSOCIATION WITH COGNITIVE FUNCTION. , 2014, 10, P402-P402.		1
586	P1-135: DIRECTED ANTERIOR-TO-POSTERIOR COMMUNICATION IN THE BRAIN IS REVERSED IN DEMENTIA WITH LEWY BODIES AND IS RELATED TO ATTENTION DEFICITS. , 2014, 10, P349-P349.		1
587	O4-01-05: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS. , 2014, 10, P250-P250.		1
588	IC-P-076: WHITE MATTER HYPERINTENSITIES PREDICT MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN PATIENTS WITH SUBJECTIVE COGNITIVE COMPLAINTS. , 2014, 10, P42-P43.		1
589	IC-P-109: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY: A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER DISEASE. , 2014, 10, P61-P61.		1
590	O4-01-01: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA. , 2014, 10, P248-P248.		1
591	P3-096: MAGNETOENCEPHALOGRAPHY IN DEMENTIA: THE STATE OF THE ART. , 2014, 10, P663-P663.		1
592	P4-089: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P806-P807.		1
593	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, P297-P297.		1
594	F2-03-02: Early onset APOE-ε <sub>4</sub> -negative Alzheimer's disease patients show faster cognitive decline on non-memory domains. , 2015, 11, P168-P168.		1

#	ARTICLE	IF	CITATIONS
595	O3-14-04: The relation between eeg spectral analysis and clinical progression in non-demented, amyloid-positive subjects. , 2015, 11, P255-P256.		1
596	IC-P-153: Thinner Cortical Thickness in Patients With Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function. , 2016, 12, P113-P114.		1
597	P4â€153: Subjective Cognitive Decline and Progression to Dementia Due to AD and Nonâ€AD in Memory Clinic and Communityâ€Based Cohorts. Alzheimer's and Dementia, 2016, 12, P1073.	0.4	1
598	O5-07-02: Personalized Risk Estimates for Mci Patients: Taking Biomarkers Into the Clinic. , 2016, 12, P393-P393.		1
599	[P3â€386]: COMPUTED RATING SCALES FOR COGNITIVE DISORDERS FROM MRI. Alzheimer's and Dementia, 2017, 13, P1108.	0.4	1
600	[ICâ€Pâ€005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€ <sup>12</sup> AND [ <sup>18</sup> F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P13.	0.4	1
601	[P4â€525]: DATAâ€DRIVEN TAUâ€PET COVARIANCE NETWORKS ENHANCE PREDICTION OF RETROSPECTIVE COGNITIVE CHANGE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1548.	0.4	1
602	P2â€645: IMPAIRED OLFACTORY AND GUSTATORY FUNCTIONING IN PATIENTS WITH ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT: THE NUDAD PROJECT. Alzheimer's and Dementia, 2018, 14, P990.	0.4	1
603	ICâ€Pâ€092: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. Alzheimer's and Dementia, 2018, 14, P76.	0.4	1
604	P4â€106: DECLINE IN GREY MATTER CONNECTIVITY OVER TIME IS RELATED TO CLINICAL PROGRESSION IN MCI DUE TO AD. Alzheimer's and Dementia, 2018, 14, P1479.	0.4	1
605	P1â€602: DUTCH ONLINE REGISTRY FOR RECRUITMENT OF PARTICIPANTS FOR DEMENTIA STUDIES: HERSENONDERZOEK.NL AND BRAIN HEALTH REGISTRY. Alzheimer's and Dementia, 2018, 14, P569.	0.4	1
606	What patients want to know, and what we actually tell them: The ABIDE project. Alzheimer's and Dementia, 2020, 16, e044754.	0.4	1
607	Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: The SCIENCE project. Alzheimer's and Dementia, 2020, 16, e044783.	0.4	1
608	Trajectories of decline in cognitively complex everyday activities across the Alzheimerâ€™s disease continuum. Alzheimer's and Dementia, 2020, 16, e044787.	0.4	1
609	Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis. Alzheimer's and Dementia, 2020, 16, e045829.	0.4	1
610	Prediction of amyloid PET status using the LUMIPULSE G <sup>12</sup> â€amyloid ratio (1â€42/1â€40). Alzheimer's and Dementia, 2020, 16, e046006.	0.4	1
611	Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. Journal of the American Medical Directors Association, 2020, 21, 1436-1438.	1.2	1
612	Differential Dementia Diagnosis on Incomplete Data with Latent Trees. Lecture Notes in Computer Science, 2016, , 44-52.	1.0	1

#	ARTICLE	IF	CITATIONS
613	Neuropsychiatric Symptoms as Predictor of Poor Clinical Outcome in Patients With Vascular Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2022, , .	0.6	1
614	Atâ€home assessment of cognitive performance: Establishing norm scores for the Cognitive Online Selfâ€Test Amsterdam (COSTâ€A). <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
615	ATN classification in dementia with Lewy bodies: Association with clinical profile, cognitive decline and survival. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
616	The (non)sense of diagnostic computer tools in memory clinics: An international survey assessing the views of clinicians, patients and caregivers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
617	The incidence of young onset dementia: A systematic review and metaâ€analysis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
618	A 24-year follow-up of body mass index and cerebral atrophy. <i>Neurology</i> , 2005, 64, 1990-1991.	1.5	0
619	NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia. <i>Neurology</i> , 2005, 65, 1341-1341.	1.5	0
620	Heterogeneity of White Matter Hyperintensities in Alzheimer's Disease: Post-Mortem Quantitative MRI and Neuropathology. <i>Neuroradiology Journal</i> , 2009, 22, 51-63.	0.6	0
621	F1-01-01: Early-onset versus late-onset Alzheimer's disease: A role for APOE e4?. , 2011, 7, S89-S89.		0
622	Cerebral microbleeds and Alzheimer's disease. , 0, , 117-124.		0
623	Reply: Cerebral microbleeds in familial Alzheimer's disease. <i>Brain</i> , 2012, 135, e202-e202.	3.7	0
624	S2â€02â€01: Understanding (endo)phenotypical heterogeneity: The role of age and APOE. <i>Alzheimer's and Dementia</i> , 2012, 8, P228.	0.4	0
625	O4â€03â€01: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, P618.	0.4	0
626	S1-02-02: Clinical and neuropsychological features as predictors from MCI to Alzheimer's-type dementia. , 2013, 9, P122-P122.		0
627	O3-05-01: Physical activity, independent functioning and emotional well-being in early-onset dementia. , 2013, 9, P526-P526.		0
628	O1-09-01: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting. , 2013, 9, P144-P145.		0
629	PL-02-02: PREDICTING CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE. , 2014, 10, P162-P163.		0
630	O3-06-02: A RE-EVALUATION OF EARLY ALZHEIMER'S DISEASE BIOMARKERS ACCOUNTING FOR INACCURACY OF THE CLINICAL DIAGNOSIS. , 2014, 10, P219-P219.		0

#	ARTICLE	IF	CITATIONS
631	Interaction between cerebral small vessel disease and neurodegenerative changes. , 0, , 298-310.		0
632	O2-13-05: APOLIPOPROTEIN A-1 IS ASSOCIATED WITH DECLINE IN PRECLINICAL AD. , 2014, 10, P195-P196.		0
633	O5-02-02: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY. , 2014, 10, P291-P292.		0
634	O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA. , 2014, 10, P194-P195.		0
635	P1-223: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE. , 2014, 10, P385-P386.		0
636	IC-P-009: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P11-P12.		0
637	IC-P-085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE. , 2014, 10, P48-P49.		0
638	P1-015: PROTEIN KINASE ACTIVITY DECREASES WITH BRAAK STAGE IN HIPPOCAMPAL POSTMORTEM BRAIN TISSUE AS REVEALED BY USING A PEPTIDE-BASED MICROARRAY PLATFORM. , 2014, 10, P309-P309.		0
639	P1-385: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY, A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF A NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER'S DISEASE. , 2014, 10, P455-P456.		0
640	O2-07-04: COGNITIVE SUBTYPES IN DEMENTIA DUE TO ALZHEIMER'S DISEASE IDENTIFIED BY LATENT CLASS ANALYSIS. , 2014, 10, P178-P179.		0
641	IC-P-077: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY. , 2014, 10, P43-P44.		0
642	O4-01-06: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P250-P251.		0
643	O2-14-03: THE REST-ACTIVITY RHYTHM IS RELATED TO THE LEVEL OF PHYSICAL ACTIVITY IN EARLY-ONSET DEMENTIA. , 2014, 10, P197-P198.		0
644	IC-P-056: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE. , 2014, 10, P31-P32.		0
645	P1-134: LOSS OF NETWORK INTEGRATION IS RELATED TO COGNITIVE IMPAIRMENT IN DEMENTIA WITH LEWY BODIES. , 2014, 10, P349-P349.		0
646	P1-149: CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE. , 2014, 10, P355-P355.		0
647	P4-273: CEREBROSPINAL FLUID NEUROGRANIN AS A PROGNOSTIC MARKER IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. , 2014, 10, P884-P884.		0
648	O1-02-04: 7T T2*-WEIGHTED MRI REVEALS CORTICAL PHASE DIFFERENCES BETWEEN EARLY- AND LATE-ONSET AD. , 2014, 10, P132-P133.		0

#	ARTICLE	IF	CITATIONS
649	P1-174: CEREBROVASCULAR DISEASE IN LATE ONSET FRONTAL LOBE SYNDROME. , 2014, 10, P363-P363.		0
650	P1-415: STUDY PROTOCOL: THE EFFECT OF PHYSICAL EXERCISE ON CEREBRAL BLOOD FLOW AND COGNITION IN PATIENTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT. , 2014, 10, P465-P466.		0
651	P3-158: Grey matter network disruptions are related to amyloid beta in cognitively healthy elderly. , 2015, 11, P689-P689.		0
652	P1-174: Diagnostic impact of [18 F]flutemetamol amyloid imaging in young onset dementia. , 2015, 11, P411-P412.		0
653	P3-072: Are relations between ApoE genotype and ad-related pathology in nondemented elderly mediated by CSF apolipoproteins?. , 2015, 11, P644-P644.		0
654	O4-05-04: A four-center study on the effect of polygenic risk score on cerebrospinal fluid markers and memory decline in mild cognitive impairment patients. , 2015, 11, P279-P279.		0
655	IC-P-124: Classification of resting-state cerebral perfusion maps from patients with Alzheimer's disease and patients with frontotemporal dementia. , 2015, 11, P85-P85.		0
656	P1-093: Dementia and rapid mortality: Who's at risk?. , 2015, 11, P374-P374.		0
657	P2-298: Altered plasma and CSF levels of nutrients that enhance neuronal phospholipid synthesis in Alzheimer's disease: A retrospective cohort study. , 2015, 11, P606-P607.		0
658	P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. , 2015, 11, P414-P414.		0
659	IC-P-079: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease. , 2015, 11, P57-P57.		0
660	IC-04-03: Grey matter network disruptions are related to amyloid-beta in cognitively healthy elderly. , 2015, 11, P11-P11.		0
661	IC-P-062: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P46-P47.		0
662	O3-09-02: An eeg study into functional connectivity and hubs in Alzheimer's disease: What's going on in the posterior regions?. , 2015, 11, P237-P238.		0
663	P1-166: A prospective validation study of the predictnd tool: A diagnostic decision support tool-rationale and design of the study. , 2015, 11, P408-P408.		0
664	O2-02-06: Slow gait speed and low grip strength are related to worse attention and mental speed in patients with subjective cognitive decline and mild cognitive impairment. , 2015, 11, P177-P177.		0
665	F2-03-03: Characterization of the behavioral and dysexecutive variants of Alzheimer's disease. , 2015, 11, P168-P168.		0
666	P3-142: Alzheimer's biomarkers in daily practice (ABIDE): Study design. , 2015, 11, P679-P680.		0

#	ARTICLE	IF	CITATIONS
667	IC-P-089: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P62-P62.		0
668	P4-100: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P814-P814.		0
669	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset. , 2015, 11, P140-P142.		0
670	O3-14-02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool. , 2015, 11, P254-P255.		0
671	F4-02-02: The influence of severity of total comorbidity on cognitive decline and conversion to dementia in memory clinic visitors. , 2015, 11, P260-P261.		0
672	O5-02-03: Reduced cortical thickness in patients with subjective cognitive decline is related to clinical progression. , 2015, 11, P317-P317.		0
673	O5-05-03: Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease. , 2015, 11, P326-P326.		0
674	P1-297: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients. , 2016, 12, P534-P535.		0
675	IC-03-02: Grey Matter Connectivity is Associated with Clinical Progression in Non-Demented, Amyloid Positive Patients. , 2016, 12, P9-P10.		0
676	P2-221: Cerebral Blood Flow Measured with Phase-Contrast MRI in AD, MCI and Controls. Alzheimer's and Dementia, 2016, 12, P706.	0.4	0
677	IC-P-196: Quantification of TAU Load Using [ <sup>18</sup> F]AV-451 and PET. Alzheimer's and Dementia, 2016, 12, P141.	0.4	0
678	O3-08-01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status. Alzheimer's and Dementia, 2016, 12, P303.	0.4	0
679	P1-178: Impact of Co-Morbid Amyloid Pathology on Clinical Phenotype of Patients with Vascular Cognitive Disorders. Alzheimer's and Dementia, 2016, 12, P472.	0.4	0
680	IC-03-05: EEG Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimer's Disease And Controls. , 2016, 12, P12-P12.		0
681	P1-284: Grey Matter Connectivity is Associated With Clinical Progression in Non-Demented, Amyloid Positive Patients. Alzheimer's and Dementia, 2016, 12, P528.	0.4	0
682	P1-327: Cross-Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease. , 2016, 12, P552-P553.		0
683	IC-P-097: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, P74.	0.4	0
684	IC-P-103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P78.	0.4	0

#	ARTICLE	IF	CITATIONS
685	ICâ€Pâ€106: Crossâ€Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P80.	0.4	0
686	ICâ€Pâ€108: Cerebral Blood Flow Measured With Phaseâ€Contrast MRI in AD, MCI and Controls. Alzheimer's and Dementia, 2016, 12, P82.	0.4	0
687	P2-348: Impact of Non-Pharmacologic Interventions on Cognitive, Behavioral, and Emotional Functioning in Older Adults with Subjective Cognitive Decline: A Systematic Review of Controlled Trials. , 2016, 12, P777-P777.		0
688	P2â€282: EEGâ€Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimer's Disease and Controls. Alzheimer's and Dementia, 2016, 12, P738.	0.4	0
689	ICâ€Pâ€147: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P109.	0.4	0
690	P3â€144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts. Alzheimer's and Dementia, 2016, 12, P873.	0.4	0
691	P4â€112: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Nonâ€Demented Elderly. Alzheimer's and Dementia, 2016, 12, P1055.	0.4	0
692	P4â€191: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, P1095.	0.4	0
693	P4â€215: Quantification of Tau Load Using [ <sup>18</sup> F]AVâ€1451 and Pet. Alzheimer's and Dementia, 2016, 12, P1109.	0.4	0
694	P4â€240: Deciding About Diagnostic Testing for Alzheimerâ€™s Disease: Patientsâ€™ Views and Experiences. Alzheimer's and Dementia, 2016, 12, P1122.	0.4	0
695	O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimerâ€™s Disease. , 2016, 12, P169-P170.		0
696	O1â€05â€02: Effects of Up to 14 Years of Biobank Storage of CSF Biomarkers AB42, TTAU, and PTAU. Alzheimer's and Dementia, 2016, 12, P183.	0.4	0
697	O4â€02â€04: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P335.	0.4	0
698	O4-09-04: Towards Data-Driven Medicine in Differential Diagnostics of Neurodegenerative Diseases. , 2016, 12, P355-P355.		0
699	P1â€174: Costâ€Efficient Differential Diagnostics of Neurodegenerative Diseases Using A Stratified Approach. Alzheimer's and Dementia, 2016, 12, P469.	0.4	0
700	ICâ€Pâ€011: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients. Alzheimer's and Dementia, 2016, 12, P19.	0.4	0
701	P1-418: Cliniciansâ€™ Views and Attitudes on Shared Decision Making in Diagnostic Testing for Alzheimerâ€™s Disease. , 2016, 12, P595-P595.		0
702	P2â€335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples. Alzheimer's and Dementia, 2016, 12, P770.	0.4	0



#	ARTICLE	IF	CITATIONS
703	P2â€“342: Thinner Cortical Thickness in Patients with Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function. <i>Alzheimer's and Dementia</i> , 2016, 12, P774.	0.4	0
704	[ICâ€“Pâ€“130]: MRIâ€“BASED CLASSIFICATION ACCURACY OF DEMENTIA TYPE IS DETERMINED BY MRI MODALITY. <i>Alzheimer's and Dementia</i> , 2017, 13, P98.	0.4	0
705	[P1â€“392]: AUTOMATED SELECTION OF MULTIMODAL MRI BIOMARKERS FOR DIAGNOSIS OF DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P417.	0.4	0
706	[P1â€“009]: DETECTING COGNITIVE DISORDERS USING THE MUISTIKKO WEBâ€“BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P234.	0.4	0
707	[P2â€“473]: THE EFFECTS OF AMYLOID ON SEMANTIC COMPLEXITY IN SPONTANEOUS SPEECH IN SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P821.	0.4	0
708	[P3â€“161]: GRANULOCYTES: KEY PLAYERS IN PERIPHERAL AÎ² CLEARANCE?. <i>Alzheimer's and Dementia</i> , 2017, 13, P995.	0.4	0
709	[P3â€“226]: PROFILING PERIPHERAL METABOLIC DYSREGULATION IN ALZHEIMER'S DISEASE: THE ADDED VALUE OF MULTIPLE SIGNATURES. <i>Alzheimer's and Dementia</i> , 2017, 13, P1024.	0.4	0
710	[P3â€“375]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1102.	0.4	0
711	[P3â€“407]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1120.	0.4	0
712	[P3â€“422]: CLINICAL AND RADIOLOGICAL FINDINGS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CAA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1127.	0.4	0
713	[P3â€“566]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1195.	0.4	0
714	[P4â€“219]: [ <sup>18</sup> F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1352.	0.4	0
715	[P4â€“235]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORTAUCIPIR. <i>Alzheimer's and Dementia</i> , 2017, 13, P1364.	0.4	0
716	[ICâ€“Pâ€“037]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P33.	0.4	0
717	[ICâ€“Pâ€“055]: EFFECT OF APOEâ€“Î¼2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P45.	0.4	0
718	[ICâ€“Pâ€“085]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P69.	0.4	0
719	[ICâ€“Pâ€“095]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P74.	0.4	0
720	[ICâ€“Pâ€“106]: PREDICTING PROGRESSION IN PREâ€“DEMENTIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. <i>Alzheimer's and Dementia</i> , 2017, 13, P81.	0.4	0

#	ARTICLE	IF	CITATIONS
721	[ICâ€Pâ€10]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P87.	0.4	0
722	[ICâ€Pâ€203]: [ <sup>18</sup> F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P148.	0.4	0
723	[ICâ€Pâ€206]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P150.	0.4	0
724	[TDâ€Pâ€020]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P166.	0.4	0
725	[P1â€“250]: DECISION TREE ANALYSIS REVEALS TWO CUT-OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P342.	0.4	0
726	[P1â€“326]: DETECTING COGNITIVE DISORDERS USING MUISTIKKO WEB-BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P380.	0.4	0
727	[P1â€“440]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P451.	0.4	0
728	[P1â€“486]: OCCURRENCE AND PROFILE OF COGNITIVE IMPAIRMENT IN PATIENTS WITH HEART FAILURE, CAROTID OCCLUSIVE DISEASE AND VASCULAR COGNITIVE IMPAIRMENT: THE HEART-BRAIN CONNECTION STUDY. Alzheimer's and Dementia, 2017, 13, P475.	0.4	0
729	[P2â€“207]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID $\beta$ AND [ <sup>18</sup> F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P688.	0.4	0
730	[P2â€“242]: PROTEOMICS IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES OF DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13, P704.	0.4	0
731	[P2â€“249]: CONTACTINâ€1 IN CSF DISCRIMINATES DEMENTIA WITH LEWY BODIES (DLB) FROM AD AND NON-DEMENTED CONTROLS. Alzheimer's and Dementia, 2017, 13, P708.	0.4	0
732	[P2â€“335]: EFFECT OF APOE $\epsilon$ 2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P748.	0.4	0
733	[F1â€“03â€“04]: BIOMARKER-BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P177.	0.4	0
734	[O1â€“01â€“02]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P182.	0.4	0
735	[O1â€“05â€“03]: CSF AMYLOID BETA 1â€“42 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSIS-DEPENDENT UPWARD DRIFT. Alzheimer's and Dementia, 2017, 13, P198.	0.4	0
736	[O1â€“05â€“04]: CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER'S DISEASE: AN ASSAY COMPARISON STUDY. Alzheimer's and Dementia, 2017, 13, P199.	0.4	0
737	[O2â€“01â€“01]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE). Alzheimer's and Dementia, 2017, 13, P547.	0.4	0
738	[O2â€“10â€“06]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM. Alzheimer's and Dementia, 2017, 13, P579.	0.4	0

#	ARTICLE	IF	CITATIONS
739	[O2â€“11â€“03]: PREDICTING PROGRESSION IN PREâ€“DEMENTIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. Alzheimer's and Dementia, 2017, 13, P581.	0.4	0
740	[O3â€“06â€“04]: PROMINENT NONâ€“MEMORY DEFICITS IN AD ARE ASSOCIATED WITH A FASTER DISEASE PROGRESSION. Alzheimer's and Dementia, 2017, 13, P912.	0.4	0
741	[DTâ€“01â€“02]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT. Alzheimer's and Dementia, 2017, 13, P1474.	0.4	0
742	[P3â€“075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. Alzheimer's and Dementia, 2017, 13, P960.	0.4	0
743	P1â€“256: COMMUNICATION ON DIAGNOSTIC TESTING FOR (ALZHEIMER'S) DEMENTIA: THE ABIDEâ€“CLINICAL ENCOUNTER STUDY. Alzheimer's and Dementia, 2018, 14, P378.	0.4	0
744	P3â€“403: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECLINICAL IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1257.	0.4	0
745	O1â€“10â€“06: CONTACTINâ€“1 HAS ADDED VALUE FOR DISCRIMINATION OF DEMENTIA WITH LEWY BODIES FROM ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE. Alzheimer's and Dementia, 2018, 14, P245.	0.4	0
746	P1â€“476: CORTICAL T1â€“W/T2â€“W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS. Alzheimer's and Dementia, 2018, 14, P506.	0.4	0
747	O1â€“14â€“04: IMPACT OF WHITE MATTER HYPERINTENSITY LOCATION ON DEPRESSIVE SYMPTOMS IN MEMORY CLINIC PATIENTS: A LESIONâ€“SYMPTOM MAPPING STUDY. Alzheimer's and Dementia, 2018, 14, P259.	0.4	0
748	ICâ€“Pâ€“111: [ <sup>18</sup> F]FLORBETAPIRâ€“S SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P95.	0.4	0
749	ICâ€“Pâ€“222: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P180.	0.4	0
750	P1â€“328: CONSISTENCY OF MUISTIKKO WEBâ€“BASED COGNITIVE TEST WHILE PERFORMED AT CLINIC AND AT HOME. Alzheimer's and Dementia, 2018, 14, P418.	0.4	0
751	P2â€“350: DETECTING FRONTOTEMPORAL DEMENTIA USING A NOVEL MRI IMAGING BIOMARKER: THE ANTERIOR VERSUS POSTERIOR INDEX. Alzheimer's and Dementia, 2018, 14, P821.	0.4	0
752	P1â€“357: MEDIAN SURVIVAL IN MEMORY CLINIC COHORT IS SHORT, EVEN IN YOUNGâ€“ONSET DEMENTIA. Alzheimer's and Dementia, 2018, 14, P431.	0.4	0
753	P1â€“016: METHYLPHENIDATE IMPROVES EXECUTIVE FUNCTIONING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT: FIRST RESULTS OF THE STREAMâ€“VCI STUDY. Alzheimer's and Dementia, 2018, 14, P270.	0.4	0
754	P1â€“259: SEX DIFFERENCES IN CEREBROSPINAL FLUID BIOMARKER CONCENTRATIONS ACROSS CLINICAL STAGES OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P380.	0.4	0
755	O2â€“06â€“03: AMYLOIDâ€“P LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P632.	0.4	0
756	P2â€“248: CONTACTINâ€“2 AS A POTENTIAL BIOMARKER FOR MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P768.	0.4	0

#	ARTICLE	IF	CITATIONS
757	O2â€06â€05: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P13.	0.4	0
758	P2â€228: PREâ€ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA. Alzheimer's and Dementia, 2018, 14, P755.	0.4	0
759	P3â€134: CIRCULATING METABOLITES ARE ASSOCIATED WITH WHITE MATTER HYPERINTENSITIES. Alzheimer's and Dementia, 2018, 14, P1119.	0.4	0
760	P1â€297: METABOLIC BLOODâ€BASED BIOMARKERS RELATE TO BRAIN ATROPHY AND WHITE MATTER HYPERINTENSITIES IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P401.	0.4	0
761	P3â€438: PARAMETRIC IMAGING OF [ <sup>18</sup> F]FLORBETAPIR: A TESTâ€RETEST STUDY IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1281.	0.4	0
762	P3â€289: HARMONIZATION OF SCD OPERATIONALIZATION ACROSS DIFFERENT MEMORY CLINIC SETTINGS: THE EUROâ€SCD STUDY. Alzheimer's and Dementia, 2018, 14, P1191.	0.4	0
763	O2â€09â€03: DIAGNOSTIC PERFORMANCE OF ELECSYS IMMUNOASSAYS FOR CEREBROSPINAL FLUID ALZHEIMER'S DISEASE BIOMARKERS IN A NONâ€ACADEMIC MULTICENTER MEMORY CLINIC COHORT: THE ABIDE PROJECT. Alzheimer's and Dementia, 2018, 14, P641.	0.4	0
764	P2â€349: DIFFERENT COMBINATIONS OF DIAGNOSTIC TESTS DISCRIMINATE SPECIFIC SUBTYPES OF DEMENTIA. Alzheimer's and Dementia, 2018, 14, P820.	0.4	0
765	P2â€352: COMMUNICATING UNCERTAINTY WHEN DISCLOSING DIAGNOSTIC TEST RESULT: THE ABIDEâ€CLINICAL ENCOUNTER STUDY. Alzheimer's and Dementia, 2018, 14, P823.	0.4	0
766	P1â€656: NUTRITIONAL STATUS AND BODY COMPOSITION OF PATIENTS WITH AD, MCI AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD PROJECT. Alzheimer's and Dementia, 2018, 14, P593.	0.4	0
767	P2â€363: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS. Alzheimer's and Dementia, 2018, 14, P830.	0.4	0
768	P2â€134: THE ADDED VALUE OF EXTREME PHENOTYPES IN ALZHEIMER'S DISEASE CASEâ€CONTROL STUDIES. Alzheimer's and Dementia, 2018, 14, P719.	0.4	0
769	P2â€360: [ <sup>18</sup> F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P827.	0.4	0
770	P3â€264: UNBIASED METHOD TO DETERMINE CUTâ€POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION. Alzheimer's and Dementia, 2018, 14, P1176.	0.4	0
771	O2â€03â€03: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. Alzheimer's and Dementia, 2018, 14, P615.	0.4	0
772	P4â€038: IS <i>SORL1</i> AN AUTOSOMAL DOMINANT ALZHEIMER GENE?. Alzheimer's and Dementia, 2018, 14, P1447.	0.4	0
773	P2â€500: PHYSICAL PERFORMANCE IN RELATION TO COGNITIVE FUNCTIONING IN PATIENTS WITH DISORDERS ALONG THE HEARTâ€BRAIN AXIS. Alzheimer's and Dementia, 2018, 14, P921.	0.4	0
774	O2â€06â€01: [ <sup>18</sup> F]FLORBETAPIR SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P630.	0.4	0

#	ARTICLE	IF	CITATIONS
775	O5â€04â€01: A RARE GENETIC VARIANT IN THE <i>PLCG2</i> GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1648.	0.4	0
776	ICâ€Pâ€093: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P79.	0.4	0
777	ICâ€Pâ€033: LONGITUDINAL CHANGES IN GREY MATTER CONNECTIVITY ARE RELATED TO COGNITIVE DECLINE IN PRODROMAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P37.	0.4	0
778	P3â€342: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTIâ€STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES. <i>Alzheimer's and Dementia</i> , 2018, 14, P1214.	0.4	0
779	ICâ€Pâ€032: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTIâ€STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES. <i>Alzheimer's and Dementia</i> , 2018, 14, P36.	0.4	0
780	F5â€05â€04: THE USE OF RESIDUAL METHODS TO CAPTURE COGNITIVE RESERVE AND STUDY CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1633.	0.4	0
781	P1â€467: DISEASEâ€STAGEâ€SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P500.	0.4	0
782	O3â€13â€06: TAKING AMYLOID PET INTO THE CLINIC: INDIVIDUALIZED RISK PREDICTION IN MCI PATIENTS â€” THE ABIDE PROJECT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1058.	0.4	0
783	O2â€15â€06: CSF AMYLOIDâ€PEPTIDES IN DEMENTIA WITH LEWY BODIES AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P663.	0.4	0
784	O3â€14â€03: IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES FOR DEMENTIA WITH LEWY BODIES: A PROTEOMIC APPROACH. <i>Alzheimer's and Dementia</i> , 2018, 14, P1060.	0.4	0
785	O2â€15â€04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P661.	0.4	0
786	O5â€01â€03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NONâ€NEGATIVE MATRIX FACTORIZATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P1638.	0.4	0
787	P2â€284: NUTRITIONAL MARKERS ASSOCIATED WITH CLINICAL PROGRESSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P789.	0.4	0
788	P3â€617: NUTRITIONAL INTAKE IN SUBJECTIVE COGNITIVE DECLINE: ROOM FOR IMPROVEMENT?. <i>Alzheimer's and Dementia</i> , 2018, 14, P1366.	0.4	0
789	F4â€08â€01: PLASMA AMYLOID AS A PREâ€SCREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1394.	0.4	0
790	ICâ€Pâ€187: CORTICAL T1â€W/T2â€W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS. <i>Alzheimer's and Dementia</i> , 2018, 14, P156.	0.4	0
791	6071Extent of hypertensive exposure in relation to vascular brain injury and cognitive impairment using heart-brain magnetic resonance imaging; The Heart-Brain Connection Study. <i>European Heart Journal</i> , 2019, 40, .	1.0	0
792	ICâ€Pâ€100: A LONGITUDINAL STUDY OF THE EFFECTS OF EDUCATION AND INTRACRANIAL VOLUME ON COGNITIVE CHANGES AND MORTALITY RATES IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P87.	0.4	0

#	ARTICLE	IF	CITATIONS
793	F2â€¹1â€¹01: NEURODEVELOPMENTAL DIFFERENCES AND ENVIRONMENTAL INSULTS INVERSELY CORRELATE WITH AGE OF ONSET IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P515.	0.4	0
794	ICâ€¹Pâ€¹025: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE. Alzheimer's and Dementia, 2019, 15, P32.	0.4	0
795	ICâ€¹02â€¹01: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE. Alzheimer's and Dementia, 2019, 15, P1.	0.4	0
796	ICâ€¹Pâ€¹076: FDGâ€¹PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELYâ€¹DEFINED SUBGROUPS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P68.	0.4	0
797	ICâ€¹Pâ€¹015: VOXELâ€¹BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE <i>CONTINUUM</i>. Alzheimer's and Dementia, 2019, 15, P24.	0.4	0
798	P1â€¹291: THE ASSOCIATION BETWEEN AFFECTIVE SYMPTOMS AND ALZHEIMER'S DISEASE BIOMARKERS ACROSS THE DISEASE SPECTRUM. Alzheimer's and Dementia, 2019, 15, P355.	0.4	0
799	Improving patient care through a national memory clinic network. Alzheimer's and Dementia, 2020, 16, e039017.	0.4	0
800	Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort. Alzheimer's and Dementia, 2020, 16, e040152.	0.4	0
801	Determinants of cognitive decline and dementia in stage 2: The SCIENCE project. Alzheimer's and Dementia, 2020, 16, e040263.	0.4	0
802	Functional interpretation of genetic risk loci for dementia using a protein quantitative trait loci (pQTLs) approach in cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, e040774.	0.4	0
803	Amyloidâ€¹ $\beta$ deposition in cognitively normal oldestâ€¹old is associated with cortical thinning and faster memory decline. Alzheimer's and Dementia, 2020, 16, e040991.	0.4	0
804	Singleâ€¹cell profiling of circulating and brainâ€¹resident immune cells in a mouse model for amyloidosis and in aged mice. Alzheimer's and Dementia, 2020, 16, e041789.	0.4	0
805	Polygenic risk score for Alzheimerâ€¹'s disease is related to amyloid positivity in subjective cognitive decline: The SCIENCE project. Alzheimer's and Dementia, 2020, 16, e042116.	0.4	0
806	Biomarker testing in MCI patients: Deciding who to tap. Alzheimer's and Dementia, 2020, 16, e042735.	0.4	0
807	Amyloidâ€¹ $\beta$ deposition in cognitively normal oldestâ€¹old is associated with cortical thinning and faster memory decline. Alzheimer's and Dementia, 2020, 16, e042768.	0.4	0
808	Gray matter atrophy, but not vascular brain injury is related to cognitive impairment in patients with heart failure. Alzheimer's and Dementia, 2020, 16, e042892.	0.4	0
809	Dutch Brain Research Registry for online study participant recruitment: Design and first results. Alzheimer's and Dementia, 2020, 16, e044738.	0.4	0
810	An RCT to identify best practices for disclosure of amyloid imaging results in mild cognitive impairment: The ABIDE simulation study. Alzheimer's and Dementia, 2020, 16, e044761.	0.4	0

#	ARTICLE	IF	CITATIONS
811	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in non-demented memory clinic participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e045196.	0.4	0
812	Grey zone amyloid burden heralds future memory decline: The SCIENCE Project. <i>Alzheimer's and Dementia</i> , 2020, 16, e045210.	0.4	0
813	Educational video increases patients' knowledge regarding the lumbar puncture procedure: Results of a randomized controlled trial in clinical practice. <i>Alzheimer's and Dementia</i> , 2020, 16, e045719.	0.4	0
814	Plasma amyloid $\beta$ oligomerization assay as a screening test for abnormal amyloid status. <i>Alzheimer's and Dementia</i> , 2020, 16, e045754.	0.4	0
815	CSF biomarkers for frontotemporal dementia and its pathological subtypes. <i>Alzheimer's and Dementia</i> , 2020, 16, e045851.	0.4	0
816	Associations of brain connectivity with disease progression and cognitive dysfunction in autosomal-dominant Alzheimer disease depend on imaging modality. <i>Alzheimer's and Dementia</i> , 2020, 16, e045942.	0.4	0
817	Study partner- and self-reported difficulties in cognitively complex everyday activities in participants without objective cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e046015.	0.4	0
818	A Cystatin C Cleavage ELISA Assay as a Quality Control Tool for Determining Sub-Optimal Storage Conditions of Cerebrospinal Fluid Samples in Alzheimer's Disease Research. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1367-1377.	1.2	0
819	Clinical Evaluation and Treatment of Cognitive Dysfunction and Dementia. , 2009, , 103-127.		0
820	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022, 3, 100128.	0.4	0
821	Clinical and analytical comparison of three assays for plasma p $\tau$ isoforms on an ultrasensitive platform. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
822	Psychosocial effects of Corona virus measures on (pre-)dementia patients during 2 <sup>nd</sup> lockdown. <i>Alzheimer's and Dementia</i> , 2021, 17, e053995.	0.4	0
823	Can we improve clinical trial design in Alzheimer's disease? The participants point of view. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
824	Measuring synaptic loss in early AD stages: Trajectories of SNAP25 and SYT1 using serial CSF sampling. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
825	A stepwise approach towards diagnostic workup in dementia using online cognitive tools. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
826	Mapping associations across multiple aspects of Alzheimer disease and the role of CSF biomarkers in individuals without dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
827	Longitudinal [ <sup>18</sup> F]flortaucipir PET: Comparison of quantitative and semi-quantitative parameters. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
828	Everyday functioning in a community-based volunteer population: Factors associated with concordance between participant and study partner's Report. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
829	Identifying and characterizing patterns of functional decline in memory clinic patients. Alzheimer's and Dementia, 2021, 17, .	0.4	0
830	Residual approaches to capture resilience and resistance in aging and Alzheimer's disease: A meta-analysis. Alzheimer's and Dementia, 2021, 17, .	0.4	0
831	Novel CSF inflammatory markers MIF and TREM1 are increased in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
832	An accurate diagnosis contributes to delayed institutionalization and mortality: The ABIDE Project. Alzheimer's and Dementia, 2021, 17, .	0.4	0
833	Subjective cognitive decline and self-reported sleep at a memory clinic: The SCIENCE project. Alzheimer's and Dementia, 2021, 17, .	0.4	0
834	Cognitive decline in possible vascular cognitive impairment (VCI): Does the form of vascular brain injury matter?. Alzheimer's and Dementia, 2021, 17, .	0.4	0
835	Predicting institutionalization and mortality across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
836	CSF protein panels reflecting multiple pathophysiological mechanisms for early and specific diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
837	Young-onset dementia in memory clinics in the Netherlands: PRECODE-GP. Alzheimer's and Dementia, 2021, 17, e053524.	0.4	0
838	Title is missing!. , 2020, 15, e0226784.		0
839	Title is missing!. , 2020, 15, e0226784.		0
840	Title is missing!. , 2020, 15, e0226784.		0
841	Title is missing!. , 2020, 15, e0226784.		0
842	Clinicians' communication with patients receiving a MCI diagnosis: The ABIDE project. , 2020, 15, e0227282.		0
843	Clinicians' communication with patients receiving a MCI diagnosis: The ABIDE project. , 2020, 15, e0227282.		0
844	Clinicians' communication with patients receiving a MCI diagnosis: The ABIDE project. , 2020, 15, e0227282.		0
845	Clinicians' communication with patients receiving a MCI diagnosis: The ABIDE project. , 2020, 15, e0227282.		0
846	The majority of the patients with a monogenic predisposition for dementia did not fulfill current criteria for genetic testing.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e052075.	0.4	0